Centre for Drug Safety Science (CDSS)
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Translational Medicine
Abstract
The use of drugs as medicines has made an enormous contribution to human health with the drug discovery process being directed to most aspects of human disease. However, all drugs are associated with side effects or adverse drug reactions (ADRs) which vary in frequency and severity dependent on the drug and patient population. The overall burden is large to both the NHS and Industry.
We have shown that at least 6.5% of all adult admissions to hospitals are due to ADRs and that approximately 15% of inpatients suffer an ADR during hospitalisation. Extrapolated nationally, ADRs are thought to cost the NHS in England in excess of £637 million annually, or approximately £5000 per hospital bed per year. This is a conservative estimate and is likely to be much higher. Our findings in the UK have been replicated in many countries showing that ADRs are a global health issue.
ADRs can lead to withdrawal or restricted use of drugs, even if the ADR occurs in only a minority of patients. This can impede the use of otherwise effective drugs being prescribed by physicians for the majority of patients who benefit from the drug without developing ADRs. The whole issue of drug safety also has a major impact on the profitability of the pharmaceutical industry, and thus the economy of the UK.
The MRC Centre for Drug Safety Science (CDSS) was therefore created in 2008 as a collaboration between the Universities of Liverpool (UoL) and Manchester (UoM) in response to a perceived need to establish a National Centre to investigate mechanisms of ADRs.
An infrastructure that allows pre-clinical and clinical scientists to work side-by-side using cutting-edge technologies to analyse well-defined clinical samples has been created in CDSS. Progress has been made in our understanding of the mechanisms of drug-induced liver injury and drug-induced hypersensitivity, including the identification of genetic predisposing factors and the development of improved diagnostic tests. Over the next 5 years our innovative findings will be translated into better clinical care for patients, improved drug development for Pharmaceutical Industry and better information for Regulators. Furthermore, our infrastructure will be extended to evaluate drug side effects associated with the kidney, the gastrointestinal tract and the cardiovascular system. Collectively, the findings from the CDSS and its collaborators will provide a better understanding of risk of ADRs and improve patient outcomes.
We will continue to work closely with scientists from the pharmaceutical industry and from regulatory authorities in a non-competitive manner that will allow us to access company-specific drugs and patient samples which provide us with the tools to address industry-wide drug safety challenges. At the same time we will act as a forum for training and knowledge exchange with all drug safety science professionals (be they in academia, health care providers, industry or regulatory authorities) which will be significantly enhanced by our expanded training programme for non-clinical and clinical scientists. This will allow us to improve capacity in drug safety science in the UK for all relevant stakeholders. We will continue our patient and public engagement activities at all levels in order to ensure that our aims and objectives are refined to make patients a central focus of the research and training activities in the Centre.
Thus the new mission statement for the Centre is "to use the critical mass and knowledge in drug safety science that we have now accrued within the Centre to undertake leading edge science, and train the next generation of drug safety scientists, to understand the fundamental mechanisms of clinically important and currently relevant adverse drug reactions in order to develop strategies to improve the benefit-risk ratio of current and new medicines, for the benefit of patients, industry and regulators."
We have shown that at least 6.5% of all adult admissions to hospitals are due to ADRs and that approximately 15% of inpatients suffer an ADR during hospitalisation. Extrapolated nationally, ADRs are thought to cost the NHS in England in excess of £637 million annually, or approximately £5000 per hospital bed per year. This is a conservative estimate and is likely to be much higher. Our findings in the UK have been replicated in many countries showing that ADRs are a global health issue.
ADRs can lead to withdrawal or restricted use of drugs, even if the ADR occurs in only a minority of patients. This can impede the use of otherwise effective drugs being prescribed by physicians for the majority of patients who benefit from the drug without developing ADRs. The whole issue of drug safety also has a major impact on the profitability of the pharmaceutical industry, and thus the economy of the UK.
The MRC Centre for Drug Safety Science (CDSS) was therefore created in 2008 as a collaboration between the Universities of Liverpool (UoL) and Manchester (UoM) in response to a perceived need to establish a National Centre to investigate mechanisms of ADRs.
An infrastructure that allows pre-clinical and clinical scientists to work side-by-side using cutting-edge technologies to analyse well-defined clinical samples has been created in CDSS. Progress has been made in our understanding of the mechanisms of drug-induced liver injury and drug-induced hypersensitivity, including the identification of genetic predisposing factors and the development of improved diagnostic tests. Over the next 5 years our innovative findings will be translated into better clinical care for patients, improved drug development for Pharmaceutical Industry and better information for Regulators. Furthermore, our infrastructure will be extended to evaluate drug side effects associated with the kidney, the gastrointestinal tract and the cardiovascular system. Collectively, the findings from the CDSS and its collaborators will provide a better understanding of risk of ADRs and improve patient outcomes.
We will continue to work closely with scientists from the pharmaceutical industry and from regulatory authorities in a non-competitive manner that will allow us to access company-specific drugs and patient samples which provide us with the tools to address industry-wide drug safety challenges. At the same time we will act as a forum for training and knowledge exchange with all drug safety science professionals (be they in academia, health care providers, industry or regulatory authorities) which will be significantly enhanced by our expanded training programme for non-clinical and clinical scientists. This will allow us to improve capacity in drug safety science in the UK for all relevant stakeholders. We will continue our patient and public engagement activities at all levels in order to ensure that our aims and objectives are refined to make patients a central focus of the research and training activities in the Centre.
Thus the new mission statement for the Centre is "to use the critical mass and knowledge in drug safety science that we have now accrued within the Centre to undertake leading edge science, and train the next generation of drug safety scientists, to understand the fundamental mechanisms of clinically important and currently relevant adverse drug reactions in order to develop strategies to improve the benefit-risk ratio of current and new medicines, for the benefit of patients, industry and regulators."
Technical Summary
Adverse drug reactions (ADRs) are a major public health problem. The Centre for Drug Safety Science (CDSS) has developed an integrated chemical, biochemical, molecular, cellular and genetic approach to analyse the fundamental and complex mechanisms of ADRs in both in vitro and in vivo models. We have a matrix approach for the: a) collection and biobanking of clinical material; b) construction of experimental methods with appropriate statistical and informatic modelling and c) application of state of the art qualitative and quantitative bioanalytical methodologies in order to be able to define the chemical, biological and genetic basis of clinically-relevant ADRs. This allows us to address each specific issue in a fundamental manner, but also to operate with efficiency and effectiveness in the CDSS across both established and newly emerging safety issues.
The CDSS provides critical mass for bioanalysis in terms of equipment and specialised personnel for both the execution of research and for training the next generation of drug safety scientists (clinical and non-clinical). We have a truly inter-disciplinary environment within CDSS with pharmacologists, chemists, cell biologists, molecular biologists, geneticists, computational biologists, mathematicians, modellers, immunologists and clinicians working side-by-side with the aim of taking our findings from the bench to the bedside to application, and also in the reverse direction.
Collaboration is critical for the maintenance of the technical capability of the CDSS. Thus we work closely with industry scientists and regulators, to develop and apply new scientific methods that become fit for purpose with respect to hazard identification and risk analysis for both established and new classes of therapeutic agents.
The comprehensive approach adopted by the CDSS is designed to reduce the burden of ADRs for both patients and for Industry, thus achieving the dual aims of improving patient health and creating wealth.
The CDSS provides critical mass for bioanalysis in terms of equipment and specialised personnel for both the execution of research and for training the next generation of drug safety scientists (clinical and non-clinical). We have a truly inter-disciplinary environment within CDSS with pharmacologists, chemists, cell biologists, molecular biologists, geneticists, computational biologists, mathematicians, modellers, immunologists and clinicians working side-by-side with the aim of taking our findings from the bench to the bedside to application, and also in the reverse direction.
Collaboration is critical for the maintenance of the technical capability of the CDSS. Thus we work closely with industry scientists and regulators, to develop and apply new scientific methods that become fit for purpose with respect to hazard identification and risk analysis for both established and new classes of therapeutic agents.
The comprehensive approach adopted by the CDSS is designed to reduce the burden of ADRs for both patients and for Industry, thus achieving the dual aims of improving patient health and creating wealth.
Planned Impact
The beneficiaries from research in the Centre for Drug Safety Science are:
1. Academia
- Publishing our research in high-impact journals will ensure that the science-base grows in the physiological, pharmacological and toxicological responses to medicines
- As an international centre of excellence for drug safety science we will continue to bring together diverse groups of experts in order to enhance our specific research programmes. This will particularly relate to researchers who have previously had no experience in the drug safety science field.
- Other national and international academic groups that are working on specific aspects of drug safety science will gain from collaborative links with CDSS, either from access to our clinical samples, access to our cross-cutting technologies, or access to our intellectual expertise.
- The strong training element of the CDSS will ensure that non-clinical and clinical academic capacity in drug safety science is enhanced. The comprehensive training in highly integrated projects involving state-of-the-art academic fields from pharmacology through to medicinal chemistry will produce 'rounded' scientists with sought-after skill-sets who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK.
2. Health Service providers
- Knowledge gained from the CDSS will lead to changes to drug labels and more effective prescribing
- Data produced by the CDSS will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies
- Scientific outputs from the Centre will ultimately reduce ADR frequency and their associated financial burden
- Continued training will increase the capacity in Clinical Pharmacology and Therapeutics
- The novelty in design of clinical studies, with patient input where appropriate, will provide the framework for further studies worldwide to replicate and advance the findings from CDSS.
3. Pharmaceutical Industry
- Scientists from the pharmaceutical industry will continue to use the CDSS as a focal point for non-competitive research
- The CDSS will continue to develop and run workshops on issues of importance to the pharmaceutical industry by bringing together appropriate experts from industry and the academic sector that will build new collaborations (not necessarily with Centre scientists) and drive novel scientific plans.
- The CDSS will allow industry scientists to spend sabbatical time in an academic setting, improving both personal development and industry-academia interactions.
- Scientific outputs from the CDSS will be used to develop drugs with better benefit:risk profiles
4. Diagnostics Sector
- Advances in mechanistic understanding of ADRs will open up new opportunities for the development of diagnostic and prognostic testing strategies that can be commercialised by the diagnostics sector leading to an improvement in the benefit:risk of drugs
5.Regulatory Authorities
- Regulatory scientists will input into and gain benefit from the CDSS workshops
- CDSS scientists will continue to provide expertise to various advisory committees of the MHRA and EMA.
- Scientific outputs from the CDSS enhance the ability of drug regulators to include the relevant information in drug labels. This will thereby contribute towards better evidence-based policy making at a global level.
6.Patients and the General Public
- By feeding knowledge and scientific advances through to other stakeholder groups, we will ultimately reduce the incidence of ADRs and allow for the pharmaceutical industry to develop safer drugs. These improvements will clearly have a major impact on enhancement of the clinical care of patients thereby leading to an improvement in quality of life.
- The general public retains a significant interest in drug safety and the CDSS will educate the public in their perception of risks associated with medicines.
1. Academia
- Publishing our research in high-impact journals will ensure that the science-base grows in the physiological, pharmacological and toxicological responses to medicines
- As an international centre of excellence for drug safety science we will continue to bring together diverse groups of experts in order to enhance our specific research programmes. This will particularly relate to researchers who have previously had no experience in the drug safety science field.
- Other national and international academic groups that are working on specific aspects of drug safety science will gain from collaborative links with CDSS, either from access to our clinical samples, access to our cross-cutting technologies, or access to our intellectual expertise.
- The strong training element of the CDSS will ensure that non-clinical and clinical academic capacity in drug safety science is enhanced. The comprehensive training in highly integrated projects involving state-of-the-art academic fields from pharmacology through to medicinal chemistry will produce 'rounded' scientists with sought-after skill-sets who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK.
2. Health Service providers
- Knowledge gained from the CDSS will lead to changes to drug labels and more effective prescribing
- Data produced by the CDSS will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies
- Scientific outputs from the Centre will ultimately reduce ADR frequency and their associated financial burden
- Continued training will increase the capacity in Clinical Pharmacology and Therapeutics
- The novelty in design of clinical studies, with patient input where appropriate, will provide the framework for further studies worldwide to replicate and advance the findings from CDSS.
3. Pharmaceutical Industry
- Scientists from the pharmaceutical industry will continue to use the CDSS as a focal point for non-competitive research
- The CDSS will continue to develop and run workshops on issues of importance to the pharmaceutical industry by bringing together appropriate experts from industry and the academic sector that will build new collaborations (not necessarily with Centre scientists) and drive novel scientific plans.
- The CDSS will allow industry scientists to spend sabbatical time in an academic setting, improving both personal development and industry-academia interactions.
- Scientific outputs from the CDSS will be used to develop drugs with better benefit:risk profiles
4. Diagnostics Sector
- Advances in mechanistic understanding of ADRs will open up new opportunities for the development of diagnostic and prognostic testing strategies that can be commercialised by the diagnostics sector leading to an improvement in the benefit:risk of drugs
5.Regulatory Authorities
- Regulatory scientists will input into and gain benefit from the CDSS workshops
- CDSS scientists will continue to provide expertise to various advisory committees of the MHRA and EMA.
- Scientific outputs from the CDSS enhance the ability of drug regulators to include the relevant information in drug labels. This will thereby contribute towards better evidence-based policy making at a global level.
6.Patients and the General Public
- By feeding knowledge and scientific advances through to other stakeholder groups, we will ultimately reduce the incidence of ADRs and allow for the pharmaceutical industry to develop safer drugs. These improvements will clearly have a major impact on enhancement of the clinical care of patients thereby leading to an improvement in quality of life.
- The general public retains a significant interest in drug safety and the CDSS will educate the public in their perception of risks associated with medicines.
Organisations
- University of Liverpool (Lead Research Organisation)
- Academy of Finland (Collaboration)
- Otsuka Pharmaceutical (Collaboration)
- Robert Bosch Foundation (Collaboration)
- Karolinska Institute (Collaboration)
- The Golden Helix Foundation (Collaboration)
- Gemini Biosciences Ltd. (Collaboration)
- Leiden University Medical Center (Collaboration)
- The Federal Institute for Drugs and Medical Devices (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- MC Diagnostics (Collaboration)
- Sysmex Corporation (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- ASLAN Pharmaceuticals (Collaboration)
- Allecra Therapeutics SAS (Collaboration)
- Novartis (Collaboration)
- Newcastle University (Collaboration)
- UCB Pharma (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Diabetes UK (Collaboration)
- MERCK (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University of Patras (Collaboration)
- Uppsala University (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Bio.logis Genetic Information Management GMBH (Collaboration)
- St Antonius Hospital (Collaboration)
- Medicines for Malaria Venture (MMV) (Collaboration)
- ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST (Collaboration)
- Medical University of Vienna (Collaboration)
- Novartis Institutes for BioMedical Research (NIBR) (Collaboration)
- ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (Collaboration)
- KNMP Holding B.V. (Collaboration)
- Sengenics (Collaboration)
- Amgen Inc (Collaboration)
- Pfizer Ltd (Collaboration)
- University of Ljubljana (Collaboration)
- LGC Ltd (Collaboration)
- Illumina Inc. (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- McLaren Applied Technologies (Collaboration)
- Liverpool Health Partners (Collaboration)
- Andalusian Health Service (Collaboration)
- University College London (Collaboration)
- University of Manchester (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Astex Pharmaceuticals (Collaboration)
- Oncological Referral Centre (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Paul Sabatier University (University of Toulouse III) (Collaboration)
- F. Hoffmann-La Roche AG (Collaboration)
- Liverpool Heart and Chest Hospital NHS Foundation Trust (Collaboration)
Publications
Abdullahi ST
(2019)
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
in British journal of clinical pharmacology
Abu-Alainin W
(2016)
UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.
in The Journal of pathology
Al-Naher A
(2018)
Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.
in British journal of clinical pharmacology
Alfirevic A
(2017)
Genomics of Adverse Drug Reactions.
in Trends in pharmacological sciences
Alfirevic A
(2016)
Medical and Health Genomics
Alfirevic A
(2019)
Genetic testing for prevention of severe drug-induced skin rash.
in The Cochrane database of systematic reviews
Alfirevic A
(2015)
Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.
in Pharmacogenomics
Alfirevic A
(2014)
Phenotype standardization for statin-induced myotoxicity.
in Clinical pharmacology and therapeutics
Alhilali KA
(2019)
Characterization of Healthy Donor-Derived T-Cell Responses Specific to Telaprevir Diastereomers.
in Toxicological sciences : an official journal of the Society of Toxicology
Ali SE
(2020)
Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury.
in Chemical research in toxicology
Amali M
(2017)
Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts
in Chemical Research in Toxicology
Amali MO
(2017)
Detection of drug-responsive B lymphocytes and antidrug IgG in patients with ß-lactam hypersensitivity.
in Allergy
Antoine DJ
(2015)
Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury.
in Hepatology (Baltimore, Md.)
Antoine DJ
(2016)
How to treat paracetamol overdose and when to do it.
in Expert review of clinical pharmacology
Antoniou M
(2019)
Biomarker-guided trials: Challenges in practice.
in Contemporary clinical trials communications
Ariza A
(2022)
Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients.
in Chemical research in toxicology
Arshad U
(2020)
Critical considerations for targeting colorectal liver metastases with nanotechnology.
in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Asiimwe IG
(2022)
Drug-Drug-Gene Interactions in Cardiovascular Medicine.
in Pharmacogenomics and personalized medicine
Asiimwe IG
(2021)
Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda.
in Clinical pharmacology and therapeutics
Asiimwe IG
(2022)
Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm.
in CPT: pharmacometrics & systems pharmacology
Attar SG
(2019)
Working together to deliver stratified medicine research effectively.
in British medical bulletin
Baker EH
(2021)
A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.
in British journal of clinical pharmacology
Baranova EV
(2017)
Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
in Journal of thrombosis and haemostasis : JTH
Barber JA
(2015)
Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.
in Toxicological sciences : an official journal of the Society of Toxicology
Barton CD
(2018)
Identifying cisplatin-induced kidney damage in paediatric oncology patients.
in Pediatric nephrology (Berlin, Germany)
Bell CC
(2018)
Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study.
in Toxicological sciences : an official journal of the Society of Toxicology
Belley-Cote EP
(2015)
Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.
in Thrombosis and haemostasis
Bellis JR
(2014)
Clinical coding of prospectively identified paediatric adverse drug reactions--a retrospective review of patient records.
in BMC pharmacology & toxicology
Bellis JR
(2014)
Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis.
in British journal of anaesthesia
Bellis JR
(2014)
Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital.
in British journal of clinical pharmacology
Bhogal T
(2021)
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.
in Leukemia & lymphoma
Bloch KM
(2014)
Pharmacogenetics of antiepileptic drug-induced hypersensitivity.
in Pharmacogenomics
Bollegala D
(2018)
Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach
in JMIR Public Health and Surveillance
Bourgeois S
(2021)
Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration.
in EBioMedicine
Bowden DL
(2018)
Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response.
in Journal of proteomics
Bracken L
(2016)
PAEDIATRIC ADVERSE DRUG REACTIONS (ADRS): A COMPARISON OF A NEWLY DEVELOPED AVOIDABILITY TOOL TO EXISTING HALLAS ASSESSMENTS.
in Archives of disease in childhood
Bracken LE
(2017)
Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool.
in PloS one
Brøsen K
(2017)
Open letter on access to the BIA 10-2474 clinical trial data.
in Lancet (London, England)
Burn J
(2018)
Direct oral anticoagulants versus warfarin: is new always better than the old?
in Open heart
Carr D
(2014)
Genome-wide association study of nevirapine hypersensitivity in a malawian HIV-infected population
in Clinical and Translational Allergy
Carr D
(2014)
CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population
in Clinical and Translational Allergy
Carr DF
(2017)
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury.
in Pharmacology & therapeutics
Carr DF
(2019)
Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
in Clinical pharmacology and therapeutics
Carr DF
(2017)
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
in The Journal of antimicrobial chemotherapy
Carr DF
(2018)
Biomarkers of adverse drug reactions.
in Experimental biology and medicine (Maywood, N.J.)
Carr DF
(2019)
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
in The British journal of dermatology
Carr DF
(2014)
Pharmacogenomics: Current State-of-the-Art.
in Genes
| Description | Clinical Pharmacology in the NHS report |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| URL | http://www.bps.ac.uk/details/news/6901701/BPS-Warns-More-Clinical-Pharmacologists-Needed-to-Improve-... |
| Description | Clinical Pharmacology: A dynamic medical specialty essential for UK healthcare |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| URL | https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Clinical-Pharmacology-A-dynamic-medical-speci... |
| Description | Ensuring UK leadership in experimental medicine |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| URL | https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Assets/Ensuring-UK-leadership-in-experimental... |
| Description | MEMBER OF 2014/15 quinquennial review (QQR) of the NC3Rs. |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | TO advise the MRC and BBSRC on: the effectiveness, quality and impact of the NC3Rs' activities over the past 5 years (2010-2014); the strategic approach and specific plans for the future; and value for money and future allocation of resources. |
| Description | Meeting to discuss clinical pharmacology in the NHS with Stephen Powis/Keith Ridge BPS/ NHS April 2018 |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | to ensure Clinical pharmacology is on the national agenda for consideration in improving healthcare provision and better understanding of pharmacology and thereapeutics |
| Description | Member of MHRA Clinical Trials, Biologicals and Vaccines EAG |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.gov.uk/government/organisations/commission-on-human-medicines/about/membership#clinical-... |
| Description | Member of SCAHT Scientific Advisory Board |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Membership of the Hepatoxicity SIG Steering Committee (Dan Antoine) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Re-appointment to Commission on Human Medicines at MHRA for Professor Park |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | SJS awareness event launch - House of Commons |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Rt Honorable Margaret Hodge supported the awareness campaign to raise awareness in respect of SJS and the impacts it has on survivors and families - an adjournmment debate will be held in March to support the awarness to assit in new policies at Department of Health being implemented. |
| Description | . Characterization of the chemical and antigenic signals transferred in exosomes between liver and immune cells; BBSRC DTP Case Studentship. |
| Amount | £100,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | 3DBioNet: an integrated technological platform for 3D micro-tissues |
| Amount | £626,046 (GBP) |
| Funding ID | MR/R025762/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 02/2022 |
| Description | An investigation into bosutinib-induced diarrhoea. |
| Amount | £164,779 (GBP) |
| Organisation | Pfizer Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 06/2016 |
| Description | Application of in vitro cell culture platforms to study the intrinsic immunogenicity of MK3207 and MK0974 - awarded to Dean Naisbitt |
| Amount | £265,000 (GBP) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | 12/2016 |
| End | 11/2018 |
| Description | Applying innovative technologies to improve the benefit-risk ratio of drugs: developing a national resource underpinned by the infrastructure of the MRC Centre for Drug Safety Science |
| Amount | £5,000,000 (GBP) |
| Funding ID | MR/M009114/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | Bridging and accelerating the translation of novel scientific findings for health and wealth gain |
| Amount | £400,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 09/2016 |
| Description | CDSS DILI Project |
| Amount | £110,000 (GBP) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | 12/2016 |
| End | 06/2018 |
| Description | Definition of the naturally-processed drug-peptide adducts that can act as functional T-cell antigens |
| Amount | £518,516 (GBP) |
| Funding ID | MR/R009635/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2021 |
| Description | Development of screening approaches to assess to intrinsic immunogenicity of drugs and novel chemicals |
| Amount | £411,338 (GBP) |
| Funding ID | BB/R008108/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Drug induced liver injury due to tuberculosis treatment: predictive biomarkers and genetic associations |
| Amount | £71,427 (GBP) |
| Organisation | Newton Fund |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 03/2018 |
| Description | Exploiting the soluble isoform of immune checkpoint receptor CTLA-4 to improve the treatment of cancer (L Dahal) |
| Amount | £248,333 (GBP) |
| Organisation | North West Cancer Research (NWCR) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2023 |
| Description | FP7 EU funding award (Prediction ADR) |
| Amount | £647,547 (GBP) |
| Funding ID | 602108 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2013 |
| End | 08/2016 |
| Description | FUTURE initiative |
| Amount | £1,000,699 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2015 |
| End | 11/2019 |
| Description | Horizon 2020 - Ubiquitous pharmacogenomics (U-PGx) (Munir Pirmohamed and Richard Turner) |
| Amount | € 1,078,196 (EUR) |
| Funding ID | 668353 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2016 |
| End | 12/2020 |
| Description | ITTP Studentship: Evaluation of Organoids and Systems Biology to develop Adverse Outcome Pathways of Gastrointestinal Toxicity |
| Amount | £90,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Identification of efficacy predictors for clopidogrel using integrated systems pharmacology approach |
| Amount | £66,000 (GBP) |
| Organisation | Newton Fund |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 02/2018 |
| Description | Industry Programme Manager |
| Amount | € 25,320 (EUR) |
| Organisation | Servier Laboratories |
| Department | International Research Institute Servier |
| Sector | Private |
| Country | France |
| Start | 06/2016 |
| End | 06/2018 |
| Description | Industry Programme Manager |
| Amount | £150,000 (GBP) |
| Organisation | Amgen Inc |
| Sector | Private |
| Country | United States |
| Start | 05/2016 |
| End | 04/2018 |
| Description | KNOWLEDGE TRANSFER PARTNERSHIP between The University of Liverpool and MC Diagnostics Limited |
| Amount | £60,101 (GBP) |
| Funding ID | KTP 11617 |
| Organisation | MC Diagnostics |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 05/2021 |
| Description | KNOWLEDGE TRANSFER PARTNERSHIP between The University of Liverpool and MC Diagnostics Limited |
| Amount | £122,022 (GBP) |
| Funding ID | KTP 11617 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 05/2021 |
| Description | Liverpool Health Partners - Drugs Theme Project Manager |
| Amount | £40,000 (GBP) |
| Organisation | Liverpool Health Partners |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 12/2016 |
| Description | MRC CASE studentship - 2014 |
| Amount | £127,327 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2018 |
| Description | MRC CASE studentship -2015 - with Servier |
| Amount | £96,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | MRC Centre for Drug Safety Science - Director |
| Amount | £2,700,000 (GBP) |
| Funding ID | MR/L006758/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 12/2019 |
| Description | MRC ITTP Studentship -2015 |
| Amount | £88,210 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | MRC ITTP studentship - 2014 |
| Amount | £84,636 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2018 |
| Description | MRC National productivity investment fund fellowship |
| Amount | £3,000,000 (GBP) |
| Funding ID | MR/S000607/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 03/2021 |
| Description | MRC National productivity investment fund fellowship (Vanessa Fontana) |
| Amount | £3,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 03/2021 |
| Description | Mechanistic study into Thrombosis and Thrombocytopenia |
| Amount | £1,651,929 (GBP) |
| Funding ID | NIHR135073 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2021 |
| End | 09/2022 |
| Description | Multimorbidity Mechanism and Therapeutics Research Collaborative |
| Amount | £3,015,658 (GBP) |
| Funding ID | MR/V033867/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2024 |
| Description | Multimorbidity Mechanism and Therapeutics Research Collaborative |
| Amount | £3,769,573 (GBP) |
| Funding ID | MR/V033867/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2024 |
| Description | NIHR i4i |
| Amount | £294,002 (GBP) |
| Funding ID | ii-lb-0313-20008 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2015 |
| End | 01/2018 |
| Description | NWCR project grant - Ian Copple |
| Amount | £128,968 (GBP) |
| Funding ID | CR1070 |
| Organisation | North West Cancer Research (NWCR) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 08/2017 |
| Description | Nanoparticle interventions for metastatic cancers - Neil K |
| Amount | £497,130 (GBP) |
| Funding ID | C55939/A21094 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2019 |
| Description | North West Cancer Research project grant |
| Amount | £111,147 (GBP) |
| Funding ID | CR986 |
| Organisation | North West Cancer Research (NWCR) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 12/2015 |
| Description | North West England MRC FELLOWSHIPS in Clinical Pharmacology and Therapeutics |
| Amount | £3,052,098 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 10/2021 |
| Description | PROteKT - Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis. |
| Amount | £258,075 (GBP) |
| Organisation | J P Moulton Charitable Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 11/2016 |
| Description | PROteKT clinical study |
| Amount | £239,000 (GBP) |
| Organisation | J P Moulton Charitable Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2016 |
| Description | Pharmacogenomics of Steroid-induced Glaucoma |
| Amount | £163,820 (GBP) |
| Organisation | Fight for Sight |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 01/2023 |
| Description | Systems pharmacology approaches to drug-induced hypersensitivity reactions |
| Amount | £70,000 (GBP) |
| Organisation | Government of Malaysia |
| Sector | Public |
| Country | Malaysia |
| Start | 04/2015 |
| End | 09/2018 |
| Description | The Role of the ERK5 signalling axis in BRAF inhibitor-resistant melanoma progression (M Cross) |
| Amount | £519,684 (GBP) |
| Organisation | North West Cancer Research (NWCR) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2023 |
| Description | The interactions between Clostridium difficile, intestinal microbiota and the host response in hospitalised patients |
| Amount | £2,400,000 (GBP) |
| Funding ID | MR/K000551/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2017 |
| Description | To elute and define the nature of naturally process drug peptide adducts displayed on relevant HLA molecules (D Naisbitt) |
| Amount | £324,315 (GBP) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | 12/2019 |
| End | 12/2029 |
| Description | To examine the potential preclinical value of mechanism-based biomarkers of DILI over more established and widely accepted clinical diagnostics related to liver histopathology. (C GOLDRING) |
| Amount | £176,248 (GBP) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | 02/2020 |
| End | 02/2022 |
| Description | TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines |
| Amount | € 8,000,000 (EUR) |
| Funding ID | 116030 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2017 |
| End | 12/2021 |
| Description | Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease |
| Amount | € 14,000,000 (EUR) |
| Funding ID | 821283 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 02/2019 |
| End | 01/2024 |
| Description | UKRI Innovation / Rutherford Fund Fellowships |
| Amount | £3,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 03/2021 |
| Description | Ubiquitous Pharmacogenomics (UPGX) |
| Amount | € 15,000,000 (EUR) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 08/2016 |
| End | 12/2021 |
| Description | University of Liverpool Confidence in Concept Program - Enhancing Translation |
| Amount | £300,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 07/2016 |
| Description | WEB RADR |
| Amount | € 368,731 (EUR) |
| Funding ID | 115632 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2014 |
| End | 08/2017 |
| Description | War-PATH warfarin bundle - NIHR Global Health Group Extension |
| Amount | £473,260 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 11/2021 |
| Description | Academy of Finland - Grant review panel member, Feb 2017 |
| Organisation | Academy of Finland |
| Country | Finland |
| Sector | Public |
| PI Contribution | The Academy of Finland is the main public funding organization supporting basic research at universities and research institutes in Finland. Intense competition in our small country and wide national collaboration among researchers make it necessary and vital for us to use external international expertise for evaluation of grant applications. |
| Collaborator Contribution | invitied to participate in of one of Finlands evaluation panels in February 2017. The panel, consisting of approximately nine experts, to evaluate applications in the field of pharmaceutical research. assisted in the contribution and the promotion of Finnish science by taking part in the work of this evaluation panel. The panel that you are invited to will convene for a one-day meeting near the Academy of Finland, Helsinki, on Wednesday, 1st February 2017, 8:30am-16:00pm. Professor Véronique Préat from Louvain Drug Research Institute, Belgium, will act as chair of the panel. Prior to the meeting, the panel members are asked to write draft statements of approximately 10 applications using online evaluation forms with preset criteria. These drafts (from two experts per application) form the working material for the panel during the meeting day. Panellists are also asked to read few additional applications for the meeting. The schedule for the review process: - The call for proposals expired at the end of September 2016. - You will have access to the applications through the Academy's online services by early December 2016. - The draft evaluations will be submitted electronically. The deadline for submitting the draft statements will be two weeks before the meeting. All drafts will be made available to the panel members prior to the panel meeting. - The panel will meet on 1st February 2017 in Helsinki, Finland. - The final statements will be written during the meeting, with the help of science advisers from the Academy of Finland. |
| Impact | future collaboration in pharmaceutical research. |
| Start Year | 2017 |
| Description | Amgen project grant - Keap1 and hepatotoxicity |
| Organisation | Amgen Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Generation and Validation of Models to Probe Keap1 Adduction as a Marker of the Hepatotoxic Liability of Drug Candidates. |
| Collaborator Contribution | Scientific collaborators and oversight of project deliverables and milestones |
| Impact | None yet |
| Start Year | 2014 |
| Description | Analysis of novel serum mechanism-based biomarkers that have enhanced liver specificity for the detection of acute livery injury, cell death (apoptosis and necrosis) and inflammation. |
| Organisation | Astex Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | DILI biomarker analysis from pre-clinical NHP toxicity study |
| Collaborator Contribution | Provision of blood samples from NHP study and finance |
| Impact | Data generated from CDSS has given the company a greater understanding of the benefit-risk balance for a drug candidate which has now moved forward to clinical testing |
| Start Year | 2015 |
| Description | Collaboration with SME to utilise proteomics for drug repurposing |
| Organisation | Gemini Biosciences Ltd. |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Sudeep Pushpakom entered into a collaboration with this Drug repurposing SME and the project is currently underway. |
| Collaborator Contribution | The industrial partner will provide part of the costs for undertaking quantitative proteomics and also waive the cost of staff time. |
| Impact | We are in receipt of the results and this is currently being analysed. |
| Start Year | 2016 |
| Description | CyTof procurement |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | CyTof procurement |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | CyTof procurement |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | CyTof procurement |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | CyTof procurement |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | CyTof procurement |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
| Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
| Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
| Start Year | 2015 |
| Description | Eli Lilly (MRC Fellowship) |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Collaborator Contribution | As and industry partner, Lilly may provide a nominated representative to sit on the Scheme's programme management board to support the running and development of the scheme. The representative may take part in decision making processes to appoint Fellows. Lilly may provide £300K cash contribution to the Scheme over 4 years and may, in addition, provide in-kind contribution reflecting the time and facilities given to the Scheme by the industry partner. It is anticipated that any projects developed in collaboration with Lilly will focus on enabling science around a methodology or platform that can provide insights into an already approved product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This should produce valuable generalised publishable information of use to the scientific community as a whole. |
| Impact | None Yet |
| Start Year | 2016 |
| Description | Future Initiative |
| Organisation | Royal Liverpool and Broadgreen University Hospitals NHS Trust |
| Department | Royal Liverpool Clinical Research Unit (CRU) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | FUTURE will provide access to a stratified cohort of healthy volunteers for clinical trials who have been genotyped for drug metabolising enzyme and transporter genes that can be readily recruited for phase I healthy volunteer studies. Part 1 of FUTURE will focus on recruiting a prospective cohort of 3000 healthy volunteers. Part 2 of FUTURE will provide a business model whereby FUTURE will offer access to a panel of genotyped healthy volunteers for potential recruitment to phase I trials. The study population will be recruited through the Royal Liverpool & Broadgreen University Teaching Hospitals NHS Trust (RLBUHT). If necessary recruitment will open up to other research centres to assist reaching the recruitment target for the study. |
| Collaborator Contribution | The study population will be recruited through the Royal Liverpool & Broadgreen University Teaching Hospitals NHS Trust (RLBUHT). Some Phase 1 trials will be conducted at the Royal Liverpool Clinical Research Unit. |
| Impact | None Yet. |
| Start Year | 2015 |
| Description | GSK collaboration - lapatinib project |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Evaluation of immune mechanisms associated with lapatinib-induced liver toxicity |
| Collaborator Contribution | Collection of blood samples from five patients (and matched controls) with specific genotypes that developed liver injury, and provision of lapatinib and key metabolites (synthesised by GSK chemists) |
| Impact | None yet |
| Start Year | 2014 |
| Description | INSTITUTE OF CARDIOVASCULAR MEDICINE AND SCIENCE (ICMS) |
| Organisation | Liverpool Heart and Chest Hospital NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | University representative on the Executive Committee and Board |
| Collaborator Contribution | ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University. |
| Impact | ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University. |
| Start Year | 2015 |
| Description | INSTITUTE OF CARDIOVASCULAR MEDICINE AND SCIENCE (ICMS) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | University representative on the Executive Committee and Board |
| Collaborator Contribution | ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University. |
| Impact | ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University. |
| Start Year | 2015 |
| Description | Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown) |
| Organisation | Sengenics |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Study design and sample provision for pilot study |
| Collaborator Contribution | provision of specific test for pilot study |
| Impact | pending |
| Start Year | 2016 |
| Description | Implementation of genotype guided dosing of warfarin for patients with atrial fibrillation |
| Organisation | LGC Ltd |
| Department | Genotyping facility |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We initiated the collaboration in order to pilot our algorithm for warfarin dosing in an implementation study funded by NIHR CLAHRC NWC. In order to implement it effectively we helped to refine LGC's testing platform through lab validation and clinical input into the presentation of test results. We implemented the test in three sites within the North West Coast and worked with clinics to ensure appropriate training and information was received and collected all tests for lab validation. We are also leading on the analysis and reporting of the implementation results. |
| Collaborator Contribution | LGC have worked with us to refine their testing platform, have provided matched funding in kind and have provided staff training, and testing materials for the implementation. |
| Impact | Implementation in progress - awaiting analysis and write up of evaluation |
| Start Year | 2015 |
| Description | Investigation of immunological mechanisms relating to tolvaptan-induced hepatotoxicity |
| Organisation | Otsuka Pharmaceutical |
| Country | Japan |
| Sector | Private |
| PI Contribution | Mechanistic work to identify drug-specific T-cell responses in patient blood samples |
| Collaborator Contribution | Provision of patient samples, drug material and finance |
| Impact | None yet |
| Start Year | 2016 |
| Description | Joint Proposals & Toxicology Training and Spokes Meeting Leicester 16.5.2017 |
| Organisation | Medical Research Council (MRC) |
| Department | MRC-HPA Centre for Environment and Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meeting to discuss collaboration |
| Collaborator Contribution | Meeting to discuss collaboration and next steps |
| Impact | none as yet no impact |
| Start Year | 2017 |
| Description | Joint Proposals & Toxicology Training and Spokes Meeting Leicester 16.5.2017 |
| Organisation | University of Leicester |
| Department | MRC Toxicology Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meeting to discuss collaboration |
| Collaborator Contribution | Meeting to discuss collaboration and next steps |
| Impact | none as yet no impact |
| Start Year | 2017 |
| Description | Liver biomarker analysis of ASLAN-003 |
| Organisation | ASLAN Pharmaceuticals |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Analysis of blood samples from a clinical study to support go/no go decision making process. Samples were analysed for liver-injury-specific biomarkers |
| Collaborator Contribution | Provision of clinical samples and budget |
| Impact | Data generated by CDSS supported the company in deciding to stop clinical development of ASLAN-003 |
| Start Year | 2015 |
| Description | Liver biomarker analysis of AT-101 |
| Organisation | Allecra Therapeutics SAS |
| Country | France |
| Sector | Private |
| PI Contribution | DILI biomarker measurements from clinical samples |
| Collaborator Contribution | Provision of clinical samples and funding |
| Impact | Data for the company that gave them a greater understanding of the benefit-risk profile of the drug candidate |
| Start Year | 2015 |
| Description | Liverpool Health Partners |
| Organisation | Liverpool Health Partners |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Executive Director of Liverpool Health Partners leading on the theme of personalised medicine. Drugs are an important element of the research, teaching and service delivery undertaken within the institutions involved in LHP. 1) Personalised Health related initiatives: A central part of the therapeutics theme is to foster research in stratified medicine. A key new initiative where the therapeutics theme will be intimately involved is the Liverpool Biomedical Research Centre. This will be enhanced by a development to establish a Biomedical Research Unit at Alder Hey Hospital. In addition, working with the AHSN, we aim to introduce some form of genetic testing into clinical care by working with a diagnostics company One example is the FUTURE initiative. A project to develop a panel of healthy volunteers who have been genotyped for polymorphisms in drug metabolising enzyme and transporter genes, who can then be readily recruited for Phase I healthy volunteer studies. 2) NW Genomics Healthcare Alliance: To develop a strategy to bring together the enormous expertise that is available within the NW Coast region. This should involve a consolidation of the existing strengths by leveraging this to develop a new model which places the region on the national map as a centre of excellence for clinical care, research and education. In late 2013, LHP established the North West Coast Genomics Healthcare Alliance (NWC GHA), supported by NWC Academic Health Science Network (NWCAHSN). Chaired by Professor Munir Pirmohamed, the Alliance brings together a range of clinical and academic genomics expertise from across the region, to look at the themes of research, education and services. Now looking at building genomics into Masters qualifications at the University of Liverpool, the Alliance will also be involved in several other upcoming bids in 2015. • NWC GHA was responsible for coordinating the successful bid for the NWC Genomic Medicine Centre led by Liverpool Womens' Hospital and has established a range of genomics educational workshops for clinicians. • Liverpool PRiME. LHP has been working with Liverpool Local Enterprise Partnership and NWC AHSN to develop the Liverpool Precision in Medicine Report, produced by Price Waterhouse Coopers. This report aims to bring investment into the region in the area of precision medicine, outlining several projects which are looking for longer term funding. 3) Pharmacovigilance in LHP: Reporting of adverse drug reactions to the MHRA is an important marker of quality of care of patients. There is wide variability in reporting at present. Having convened a working group, LHP aims to improve reporting of adverse drug reactions within LHP Trusts to make the region stand out in improving drug safety. This effort will be linked to improving education and training in this area, and will also involve the prevention of drug-drug interactions. The YCWG is exploring the possibility of holding an annual event in the Mersey region to engage practitioners further. Methods to engage patients and increase patient reporting are also under investigation • The Yellow Card Working Group (YCWG). Established in May 2014 to improve adverse drug reaction reporting via the Yellow Card Scheme in LHP Trusts. A number of different initiatives and approaches have been adopted with overall reporting up 61% in 2014/15 compared with in 2013/14. . Liverpool Adverse Drug Reaction Causality Assessment Tool. A project to evaluate the implementation of the tool has been submitted to the CLAHRC North West Coast. 4) Alcohol: Alcohol misuse remains a major cause of morbidity, mortality, hospital admission and social problems within the LHP patch. There are initiatives in the community to reduce the transition from social to problem drinking, and this preventive approach is clearly important. However, for the many patients who have gone beyond this point, and are classed as alcohol dependent, there is a need to better develop how we use drugs that prevent relapse to drinking. Four areas are being targeted: (a) define the pharmacoepidemiology of current drug use by using health informatics databases; (b) develop baclofen as a treatment for alcohol dependent patients with liver impairment; (c) stratify the use of naltrexone in patients by genotyping for the mu-opioid receptor; and (d) identify new biomarkers of hepatic fibrosis/cirrhosis, and identify new drug targets.The LHP Alcohol Research Alliance (LARA) has been established to foster closer working links between alcohol related researchers in the Liverpool region. The group consists of clinicians, specialist nurses, academics and policy makers, with the aim of developing cross theme programmes that will allow a range of translational research questions to be addressed. • Alcohol Research Biobank. Initial funding has been secured from the Liverpool BRC in Personalised Health. Once established the team will be looking for larger, sustainable funding streams. •GenomALC. A collaboration has been established with an international consortium (GenomALC) to investigate the relationship between alcohol consumption, genetics and progression to alcoholic liver cirrhosis. • Alcohol Research UK has funded several Liverpool, and other national , projects to identify how drugs are used in the treatment of alcohol dependence. 5) Cardiovascular pharmacology: Cardiac disease is the major cause of death nationally, and working with 5LHCH, we intend to identify new areas which can be developed that will improve existing drug therapy and improve capability in the region. The warfarin example reflects a project which is far advanced, but other areas which are being discussed include personalised renal function monitoring in patients with heart failure being treated with diuretics and stratification of anti-platelet therapy. |
| Collaborator Contribution | Liverpool Health Partners brings together the Liverpool City Region's leading hospitals and academic institutions to improve health and deliver exemplary research, education and healthcare, specifically in Personalised Health. |
| Impact | Education Strategy across Liverpool Health Partnership Liverpool Health Partners, or LHP, is an umbrella organisation with a unique ability to bring together clinical and scientific expertise to develop and promote world-leading research, education, healthcare and innovation. Their work impacts not only the North West of England but also the rest of the UK and the whole world. |
| Start Year | 2015 |
| Description | MC Diagnostics |
| Organisation | MC Diagnostics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Partnership with MC Diagnostics which has led to the award of an NIHR i4i grant (£350K). |
| Collaborator Contribution | Partnership with MC Diagnostics which has led to the award of an NIHR i4i grant (£350K) |
| Impact | Please see publications listed under the specific grant on research fish (it is linked to that award) |
| Start Year | 2015 |
| Description | MMV research project - primaquine |
| Organisation | Medicines for Malaria Venture (MMV) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | Scientific leadership and research activities from two postdoctoral fellows |
| Collaborator Contribution | Scientific input into project Progress evaluation through monthly teleconferences |
| Impact | None yet |
| Start Year | 2014 |
| Description | McLaren Applied Technologies personalised renal function monitoring guidelines |
| Organisation | McLaren Applied Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | oollaboration initiated in order to build Uol existing NIHR CLAHRC NWC funded project developing personalised monitoring guidelines and to work towards improved testing and monitoring systems for heart failure patients taking diuretics. |
| Collaborator Contribution | McLaren colleagues are working with me to gain additional funding and are supporting the data analytics. |
| Impact | None as yet. |
| Start Year | 2015 |
| Description | Merck project grant - translational DILI biomarkers |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | Scientific leadership; development of infrastructure to support clinical sample collection relevant to the project; laboratory activities. |
| Collaborator Contribution | Scientific collaboration and oversight of milestones and deliverables |
| Impact | None yet |
| Start Year | 2014 |
| Description | NPIF Innovation Fellow project with MRC-PHE Centre for Environment and Health |
| Organisation | Imperial College London |
| Department | MRC-PHE Centre for Environment & Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research project entitled "Alcohol dependence and associated disease: determinants, pathogenesis and treatment" being led by the CDSS in Liverpool. |
| Collaborator Contribution | To be defined |
| Impact | None yet |
| Start Year | 2018 |
| Description | NPIF Rutherford Fund Fellow - Vanessa Fontana - collaborating with MRC Toxicology Unit |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Toxicology Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research project entitled "Exploring the interaction of gut microbiome, genetic and immunological factors in gastrointestinal toxicity of immune checkpoint inhibitors" is being led by CDSS in Liverpool. |
| Collaborator Contribution | To be defined |
| Impact | None yet |
| Start Year | 2018 |
| Description | Naproxen idiosyncratic drug-induced liver injury |
| Organisation | Novartis Institutes for BioMedical Research (NIBR) |
| Country | United States |
| Sector | Private |
| PI Contribution | Research project planning and hosting Novartis scientist in CDSS to perform research |
| Collaborator Contribution | Provision of drug material and finance; secondment of Novartis scientist to CDSS laboratories |
| Impact | None yet |
| Start Year | 2016 |
| Description | New mechanistic extracellular matrix-derived biomarkers to predict the progression of liver fibrosis to cirrhosis |
| Organisation | Sysmex Corporation |
| Country | Japan |
| Sector | Private |
| PI Contribution | Identification of mechanistic biomarkers of liver fibrosis |
| Collaborator Contribution | Financial |
| Impact | None yet |
| Start Year | 2015 |
| Description | Novartis (MRC Fellowship) |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Collaborator Contribution | Novartis will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows. Novartis will provide £300K cash contribution to the Scheme over 4 years and will, in addition, provide £60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors. Novartis will support the identification and development of potential projects with individual Fellowship candidates. Should the candidate(s) be successful, they will be assigned an industry co-supervisor who will provide regular input into their project. Importantly, projects will be developed such that a prolonged secondment at Novartis is built into the project plans. The secondment will allow the Fellow to access technologies and expertise that may not be available in the academic institutions and/or it will allow the fellow to work on specific aspects of their research which will contribute to the quality of the thesis. The partnership with Industry will provide individual Fellows with first-hand experience of how the pharmaceutical industry operates. |
| Impact | None yet |
| Start Year | 2016 |
| Description | PBMC responses to in vitro testing of AMG 747 and related glycine transporter type-1 (GlyT1) inhibitors |
| Organisation | Amgen Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Analysis of T-cell responses in a patient with Stevens Johnson Syndrome |
| Collaborator Contribution | Provision of patient blood sample, drug and £6K cash contribution |
| Impact | Drug-specific T cells were not detected |
| Start Year | 2015 |
| Description | Partnership with Illumina for provision of the NextBio Clinical tool |
| Organisation | Illumina Inc. |
| Department | Illumina |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have provided complex data-sets (genomic, transcriptomic, proteomic) to Illumina and asked for specific functionality in the NextBio Clinical system. |
| Collaborator Contribution | Illumina have provided training in NextBio Clinical and hae been working to try to integrate different deata types (transcriptomic, proteomic) into the software tool. |
| Impact | None yet |
| Start Year | 2016 |
| Description | Pfizer research project - bosutinib |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | An investigation into the use of ex-vivo rodent and human hepatocyte models to study bosutinib-induced liver toxicity |
| Collaborator Contribution | Scientific collaboration and oversight of project deliverables and milestones |
| Impact | None yet |
| Start Year | 2014 |
| Description | PhD supervision - Prof Mark Coles to Dr Anna Olsson-Brown |
| Organisation | University of Oxford |
| Department | Kennedy Institute of Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Anna is Prof Mark Coles PhD student |
| Collaborator Contribution | Prof Mark Coles provides PhD supervision to Dr Anna Olsson-Brown |
| Impact | Poster presentations presented by Anna Olsson-Brown at ISOP and ASCO Immuno-oncology Symposium |
| Start Year | 2016 |
| Description | Roche (MRC Fellowship) |
| Organisation | F. Hoffmann-La Roche AG |
| Country | Global |
| Sector | Private |
| PI Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Collaborator Contribution | Roche will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows. Roche will provide £300K cash contribution to the Scheme over 4 years and will, in addition, provide £60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors. It is anticipated that any projects developed in collaboration with Roche will focus on enabling science around a methodology or platform that can provide insights into an already approved [company name] product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This will produce valuable generalised publishable information of use to the scientific community as a whole. |
| Impact | None Yet |
| Start Year | 2016 |
| Description | Sengenic Immunome Protein Array - Anna Olsson-Brown |
| Organisation | Sengenics |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Collection and provision of anonymised samples for investigation into the immune related adverse events following oncological immunotherapy |
| Collaborator Contribution | Evaluation of serum samples using the Immunome protein array platform determining the presence of autoantibodies. They are also providing the data analysis for the sample pilot |
| Impact | No outputs as yet. Collaboration just concluding the initial round of analysis |
| Start Year | 2017 |
| Description | The Precision Medicine Catapult. |
| Organisation | Diabetes UK |
| Department | Precision Medicine Catapult |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Under the new partnership, the two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes. |
| Collaborator Contribution | Ensuring better patient outcomes Under the new partnership, the two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes. The Precision Medicine Catapult, created in April 2015 by Innovate UK, brings access to unique programmes, collaborations, initiatives and expertise from its global connections. It is focused on making the UK the most compelling location in the world for the development and delivery of this new targeted approach |
| Impact | this partnership will significantly increases the impact of our network's activities. We expect this collaboration to be highly effective as we work together to develop the precision medicine solutions which are revolutionising healthcare." |
| Start Year | 2015 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Andalusian Health Service |
| Country | Spain |
| Sector | Public |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Bio.logis Genetic Information Management GMBH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | KNMP Holding B.V. |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Medical University of Vienna |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Oncological Referral Centre |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Paul Sabatier University (University of Toulouse III) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Robert Bosch Foundation |
| Department | Robert Bosch Foundation for Medical Research (RBMF) |
| Country | Germany |
| Sector | Charity/Non Profit |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | St Antonius Hospital |
| Department | St. Antonius Hospital Foundation |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | The Federal Institute for Drugs and Medical Devices |
| Country | Germany |
| Sector | Public |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | The Golden Helix Foundation |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | University of Ljubljana |
| Country | Slovenia |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | University of Patras |
| Country | Greece |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | U-PGx Collaboration (Richard Turner) |
| Organisation | Uppsala University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Ubiquitous pharmacogenomics (U-PGx) is a pan-European consortium that received a 15€ million grant from the EU Horizon2020 Societal Challenges funding stream in order to deliver an international pharmacogenomics implementation initiative. Professor Sir Munir Pirmohamed and I are the UK lead investigators for this consortium. I have been involved since the preliminary project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium is undertaking a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines). |
| Collaborator Contribution | The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK. |
| Impact | One publication (listed above) in CPT, several oral presentations at regional, national & international meetings |
| Start Year | 2014 |
| Description | UCB Pharma (MRC Fellowship) |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Collaborator Contribution | UCB Celltech will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows. UCB Celltech will provide £300K cash contribution to the Scheme over 4 years and will, in addition, provide £60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors. It is anticipated that any projects developed in collaboration with UCB Celltech will focus on enabling science around a methodology or platform that can provide insights into an already approved UCB Celltech product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This will produce valuable generalised publishable information of use to the scientific community as a whole. |
| Impact | None Yet |
| Start Year | 2016 |
| Description | University of Manchester (MRC Fellowship) |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Collaborator Contribution | The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of >1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM. |
| Impact | None Yet |
| Start Year | 2016 |
| Title | METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY |
| Description | This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury. More specifically, the present invention relates to methodology for detecting particular serum biomarkers that can be used in the detection, assessment and/or diagnosis of organ(e.g. liver)or tissue (e.g. skin) injury. |
| IP Reference | CA2766739 |
| Protection | Patent application published |
| Year Protection Granted | 2011 |
| Licensed | No |
| Impact | Significant publications on the value of using these markers for predicting/detecting DILI in patients |
| Title | Method for the detection of organ or tissue injury |
| Description | Novel mechanism-based biomarkers for drug-induced liver injury (HMGB1 and CK18), and methods to measure them. |
| IP Reference | JP2012532310 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | No |
| Impact | None as of yet. |
| Title | PROteKT Trial (Stephen McWilliam) |
| Description | PROteKT is a Phase IIa randomised, controlled trial of Rosuvastatin for the prevention of aminoglycoside-induced Kidney Toxicity in children with cystic fibrosis. It is an example of drug repurposing: utilising a licenced medication for a different indication. It is hoped that this intervention will lead to benefits for children with cystic fibrosis, and to other patients receiving aminoglycoside antibiotics. This is the first human study of rosuvastatin for this indication. The trial received funding from the JP Moulton Foundation, and is currently close to completion of recruitment. Analysis is on-going, trial will be published in 2018 |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | This trial required a suitable, sensitive biomarker of aminoglycoside-induced kidney injury. Current clinical practice relies on change in serum creatinine which is an insensitive marker of early kidney toxicity. Through observational studies we identified a urine biomarker, kidney injury molecule-1, as a promising early marker of aminoglycoside-induced kidney toxicity. Developing and validating this biomarker has allowed us to use this as the primary outcome measure in this study. |
| URL | http://www.protekt-trial.org.uk/ |
| Title | TAILoR |
| Description | The intervention which is tested is Telmisartan, an Angiotensin Receptor Blocker, which is currently used in clinical practice for hypertension. The TAILoR trial is testing Telmisartan for a different indication - to see whether Telmisartin could be effective in reducing insulin resistance in HIV Positive Individuals. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | None yet |
| URL | http://www.tailortrial.org.uk/ |
| Description | 'Meet the Scientists', Liverpool World Museum, January 2016 (Richard Turner/Programme Coordinator) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | A group of approx 20 PhD Students and Postdoc researchers from the Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine, including Richard Turner from the Fellowship Scheme took part in this large public engagement activity which was a callobration between the Faculty of Health and Life Science at the University of Liverpool and the Liverpool World Museum in the city centre. They hosted five activity stand exploring the development of evidence based medicine and new innovations in genetics, big data and bioinformatics that will contribute to the development of personalised medicine. This was done through a series of simple table top activities aimed at children which provided students and postdocs with the opportunity to talk to adults about personalised medicine, clinical trials, drug safety as well as talking about their own research. The vent was very popular with over 500 people visiting the five stands that were under the banner 'Marvellous Medicine'. Angela Foxcroft, the Fellowship Programme Coordinator and Kerrie McGiveron, the CDSS Research Administrator played a key role in organising this event. Richard Turner (MRC Fellow) developed the activity explaining 'Clinical Trials' and ran the stand for the whole day. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/ |
| Description | 11th International ISSX Meeting: South Korea June 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary lecture Pharmacogenomics: relevance to personalised medicine" Symposium Non-HLA Genetic Risk Factors in Idiosyncratic Adverse Drug Reactions title of presentation is: Statin-induced Myotoxicity |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://issxbusan2016.org/schedule-at-a-glance-1/ |
| Description | 13th International Congress of Human Genetics (ICHG 2016) kyoto April 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | session conveners to 13th International Congress of Human Genetics (ICHG2016) Recent spectacular advancement in the technologies of genome analyses including next generation sequencing and in the informatics of huge data including genome sequences and medical information, are bringing exceptional opportunities for better understanding our human genome and diseases, and, furthermore, for developing more efficacious treatment for diseases. the conference showcased many exciting scientific sessions in all the fields of human genetics. the conference enabled an opportunity to share latest development in human genetics and discuss the future of human genetics. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ichg2016.org/contents/program.html |
| Description | 1st PHARMACOGENOMICS ISTANBUL SUMMIT 2015" -iSTANBUL 26th November -27th November 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pharmacogenetic Markers of Drug Efficacy and Toxicity talk and chairing a session on NOVEL TOOLS AND TECHNOLOGIES IN PEROSNAL OMICS RESEARCH Although there have been significant advances in pharmacogenetics over the last decade, only a few have been translated into clinical practice. The best example is the implementation of HLA-B*57:01 genotyping prior to the prescription of abacavir, which has virtually eliminated the problem of abacavir hypersensitivity. With new rapid genotyping technologies, regulatory modernisation, novel clinical trial designs, systems approaches and integration of pharmacogenetic data into decision support s |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.pharmacogenomicsistanbul.com/ |
| Description | 2016 KSCPT Spring Conference, Busan, Korea |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | speech title Precision Medicine: A Clinical Pharmacological Perspective. - |
| Year(s) Of Engagement Activity | 2016 |
| Description | 3rd Precision Medicine Congress 12-September 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | keynote Address title Pharmacogenomics and its role in precision medicine The conference had four streams over two days targeting the following strategic and scientific key areas:- • Strategies & Technologies to Enable Successful Implementation of Precision Medicine • Biomarkers & Companion Diagnostics Development to Deliver Precision Medicine • Integrating Personal Genomics, Big Data and Bioinformatics • Precision Medicine Therapeutic Case Studies |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.globalengage.co.uk/precision-medicine.html |
| Description | 3rd UPGX Consortium Meeting. Liverpool 19-20TH september |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Consortium meeting Projects to dates and activities measured aginst work plan • Changes and updates to guidelines • Endorsement of guidelines Update from Genotyping technology •Update Training and education of health care professionals, patients and other stakeholders |
| Year(s) Of Engagement Activity | 2018 |
| Description | 6th Burns festival of Bone and Joint Disease January 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | talk at festival on Personalised medicine in rheumatology - fact or fantasy to stimulate thinking in this area. Generated discussion and linkage between the various talks delivered to inform debate and discusion |
| Year(s) Of Engagement Activity | 2015 |
| Description | 6th International Conference Medical Genetics and Genomics in Healthcare Kuwait December 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The conference will cover a number of genetic disorders, focusing on how the use of Next-Generation Sequencing (NGS) has transformed healthcare organizations. Keynote speakers around the globe discussed the clinical benefits of omics fields in diagnostic and research for genetics disease. The conference will also have an overview discussion of the achievements and challenges upon the implementation of National Genome project in Gulf Cooperation Council countries. Topics covered: - Clinical genetics and counselling - Neuromuscular, cancer, cardiac, and metabolic genetics - Next generation sequencing as diagnostic tool - Pharmacogenomics and metagenomics in health - Preventive genetics - Newborn screening - New treatments for genetic disorders |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://algenome.com/conference/ |
| Description | A Conversation with clinicians: shaping the implementation of genomics in mainstream medicine 7th June 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Genomics England's engagement programme aims to catalyse discussions with the public and specific expert stakeholders about the potential of genomics, and issues likely to arise in its wider implementation within health services. This meeting is the only event focused on clinicians, and brings together 'clinical champions' from the PHG Foundation's Genomics in Mainstream Medicine initiative, alongside other senior clinicians from those fields. Offered a practical view on the potential of genomics for patients - and the barriers to be addressed to make it available in mainstream medical practice |
| Year(s) Of Engagement Activity | 2016 |
| Description | AASLD Hepatoxicity Special Interest Group Presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was an AASLD hepatoxicity special interest group presentation. |
| Year(s) Of Engagement Activity | 2015 |
| Description | ASCPT 2015 March 2015 New Orleans |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | GREATER UNDERSTANDING OF PERSONALIZED MEDICINE USING GENOMEWIDE APPROACHES INVITATION TO DISCUSS AT FUTURE EVENTS |
| Year(s) Of Engagement Activity | 2015 |
| Description | ATTENDANCE AT PHARMACOLOGY 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 4 DAY EVENT IN WHICH DISCUSSION AND DEBATE WHERE GENERATED Ideas shared and information built upon |
| Year(s) Of Engagement Activity | 2014 |
| Description | Academic Health Science Networks - Medicines Optimisation Event 26th November 2015 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The day is to bring together AHSN teams working on MO to share progress on projects, to solve problems together and to build knowledge; in addition, the day will allow exchange of information with NHS E, ABPI and RPS. Through this we seek to build momentum for change, improve quality of each programme and ensure spread of improvement. There will be breakout sessions including one for those with Patient Safety Collaborative workstreams on medicines. Safety - including thinking around the collaboratives Outcomes - including implementing NICE TAs, building a case for use 'value based healthcare' Patient Experience - including adherence |
| Year(s) Of Engagement Activity | 2015 |
| Description | Academic Paediatric Association conference 2016 Alder Hey Liverpool |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | •The annual Academic Paediatric Association conference Liverpool on April 14th and 15th. This is the preeminent conference for all paediatric trainees, allied healthcare professionals, scientists and consultants with an interest in academic paediatrics. areas of dicussion included Personalised medicine - discovery to implementation the application of nanotechnology in paediatric drug delivery - |
| Year(s) Of Engagement Activity | 2016 |
| Description | Annual Liverpool Research Society Conference April 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Speaker at conference on the future of personalised medicine in NHS judged oral and poster presentations |
| Year(s) Of Engagement Activity | 2018 |
| Description | Athens UPGX meeting 26th September -28th September 2016 the 1st Annual Consortium Meeting, |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | the 1st Annual Consortium Meeting, Athens to discuss Kick-off meeting report planning for Reporting Period 1, including Meetings, U-PGx Days, Deliverables and Milestones. |
| Year(s) Of Engagement Activity | 2016 |
| Description | BIG DATA WORKSHOP London 14-15th November 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | To lead a discussion in the agency and the network of where "Big Data" may have application in medicines development and regulation - a challenging task in terms not only of identifying which data would add the most value but also of when in the life cycle of a medicine it may have the most application. talk covered included a case study of genomics in terms of personalised medicine discussing the application of pharmacogenomics across the entire life cycle of a medicine with a forward thinking view on how this could be integrated more routinely into decision making. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2016/08/event_detail_001314... |
| Description | BPS Winter Meeting - 2017 (Vincent Yip) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Oral Presentation of latest findings from PhD research |
| Year(s) Of Engagement Activity | 2017 |
| Description | BPS Winter Meeting Dec 2015 (Vincent Yip) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation of latest findings from PhD research |
| Year(s) Of Engagement Activity | 2015 |
| Description | BPS Workshop - Pharmacogenomics in Drug Development 21st April 2021 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The British Pharmacological Society and the UK Pharmacogenetics and Stratified Medicine Network hosted a joint virtual meeting on 'Pharmacogenomics in Drug Development', hosted by Professor Sir Pirmohamed. training event is aimed to support pre-clinical and early drug development professionals in understanding pharmacogenomics and its relevance in drug development and clinical care. a series of expert talks, followed by afternoon group discussions sessions on: What is Pharmacogenomics - An introduction with Q&A Working together to exploit novel genetic insights with Q&A Developing the capacity and capability for stratified early phase studies with Q&A Pharmacogenomics testing and the genomic medicine service with Q&A Education and genomic testing with Q&A Requirements for preclinical to clinical transition in terms of pharmacogenomics What is the appetite and need for undertaking precision dosing early phase studies based on pharmacogenomic knowledge? How can knowledge of pharmacogenomics testing during drug development help with clinical care in the NHS? |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://www.uk-pgx-stratmed.co.uk/index.php/component/jevents/eventdetail/751/23/bps-joint-workshop-p... |
| Description | BSACI meeting September 2016 - |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | session title Anaesthetic Allergy Talk Title: Pharmacogenetics of anaesthetic allergy increased knowledge from those attending |
| Year(s) Of Engagement Activity | 2016 |
| Description | Better Safer medicines for Children and Babies (Alder Hey / UOL ) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The intention is the establishment of a Biomedical research unit BETTER, SAFER MEDICINES FOR CHILDREN AND BABIES intended to integrate Liverpool's international expertise in Child Health, Clinical Pharmacology, Stratified Medicine, Drug Safety Science and Translational Biomedical Research, into the development of safe, effective and targeted therapies for children and babies to better address their current and future health needs. chairmanship of this group to drive forward |
| Year(s) Of Engagement Activity | 2015,2016 |
| Description | Bio sensors workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Workshop to discuss Biosensors technology and capabilities and opportunities this involved UOL/ LJMU/ Industry partner |
| Year(s) Of Engagement Activity | 2017 |
| Description | Bordeaux Festival May 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 3 hour discussion on the topic of The excitement and challenges of being a clinical pharmacologist Over three days, six world-class experts come to Bordeaux to talk of the topic of their choice. pharmacoepidemiology is a rapidly evolving science, with new methods arising regularly, or new refinements to old methods. Thee event provides the opportunity to focus and examine in great depth particular topics |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://pharmacoepi.bordeaux-festival.eu/ |
| Description | British Biophysical Society 2016 Biennial Meeting July 2016 Liverpool |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | title of speech Role of transporters in drug failure the conference is dedicated to sessions covering cutting edge biophysical approaches to areas of major interest to the wider community. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.britishbiophysics.org.uk/our-meetings/119-bbs2016 |
| Description | British Pharmacological Society annual flagship meeting (2015) (Richard Turner) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation, entitled 'Investigating the prevalence, predictors and prognosis of suboptimal statin therapy early after a non-ST elevation acute coronary syndrome' concerning the the research Richard Turner has been conducting as part of his Fellowship on the North West England MRC Scheme in Clinical Pharmacology & Therapeutics. The presentation was well received and led to a thought-provoking discussion. Richard was awarded the GlaxoSmithKline Prize for clinical oral communications as a result of this presentation at the British Pharmacological Society flagship annual meeting. |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015# |
| Description | CDSS Scientific Advisory Board meeting April 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Event open to CDSS community to discuss key areas of research within the Centre Liver toxicity • Biomarkers • In vitro systems • Regenerative medicine . Hypersensitivity • Functional work • Genetics GI toxicity • Upper GI toxicity • Lower GI toxicity |
| Year(s) Of Engagement Activity | 2016 |
| Description | CDSS workshop to discuss drug-induced pancreatic injury Liverpool September 30th 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Introduction to clinical problem, mechanisms of injury, risk factors for injury and emerging biomarkers and Industry perspective and better predictive models of pancreatic injury |
| Year(s) Of Engagement Activity | 2006,2016 |
| Description | Cancer drug safety workshop 11th Feb 2021 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Joint workshop between Universities of Manchester and Liverpool Talks on the research landscape and mechanistic work for future working relationships and potential areas for collaboration across Liverpool MRC Centre and MCRC-Christie encompassing the preclinical strengths, mechanistic drug interaction research, real world clinical data and translational research To gain insight into the roles of comorbidity, polypharmacy, ethnicity and pharmacogenomics in complex patients on the efficacy and side effect profile of systemic molecular targeted agents and immunotherapy, used either alone or in combination. To understand how future projects may be developed including potential investigations utilising, for example, ePROMs and ePREMs, pharmacodynamic and toxicity biomarkers, machine learning, and real world data sets. : |
| Year(s) Of Engagement Activity | 2021 |
| Description | Chief Scientific Officer Conference 1st March 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Vision For 2020 is aimed at senior leaders and healthcare scientists at all levels to start encouraging them to look to the future. healthcare scientists across all disciplines attended the event with the aim to show the depth and breadth of expertise that there is the event covered key changes and challenges in the healthcare and healthcare science landscape, 1. Science at the heart of the constitution 2. Healthcare Scientists delivering the change 3. Emerging science 4. Building the capacity and capability for change my contribution was bringing my expertise and knowledge to the theme of Personalised medicine |
| Year(s) Of Engagement Activity | 2016 |
| Description | Clinical Pharm week |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Clin Pharm week organised by BPs shines a light on the important work of Clinical Pharmacology in NHS and the focus in 2021 was on the topic areas of Pharmacogenomics in Adult Health Pharmacogenomics in Child Health Education and Training |
| Year(s) Of Engagement Activity | 2021 |
| Description | Conference Feb 2015 Cardiff - Digital Health Assembly, |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | big data topic on the subject of: 'My Risks, My Treatment: Stratified Medicine' eHealth Industries Innovation (ehi2) Centre in partnership with the Farr Institute and the Welsh Government hosted the meeting Over three days speakers covered three main topic areas of big data, innovative business models and empowering patients and staff which ensured the event was illuminating and insightful one |
| Year(s) Of Engagement Activity | 2015 |
| Description | DHM 2016 Malaga |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Brought together researchers and physicians from different disciplines to exchange their most up-to-date data in this continually evolving field and to transfer it to clinical practice |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.eaaci-dhm.org/ |
| Description | DSRU's 8th Biennial Signal Detection Conference June 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | TO ENGAGE WITH Pharmaceutical companies from Europe uk USA to discuss progress in The pharmacogenetic basis of adverse drug reactions improved knowledge |
| Year(s) Of Engagement Activity | 2015 |
| Description | Deep Leaning Precision medicine Workshop Riva Del Garda September 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | greater awareness of impact of deep learning on precision medicine |
| Year(s) Of Engagement Activity | 2016 |
| Description | Downing Street Technical Press Conference COVID 19 2nd December 2020 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Chair of COVID 19 Vaccine Expert Working Group invited to Downing street Technical briefing to outline the process and the work undertaken to approve the Pfizer vaccine in UK |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://news.liverpool.ac.uk/2020/12/02/prof-sir-munir-pirmohamed-presents-at-downing-street-covid-1... |
| Description | ELRIG Drug Discovery conference October 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Plenary lecture 45 minute presentation of broad appeal to mostly preclinical 'drug discovery' in drug discovery research across pharma, biotech, academia and the vendor community. The meeting will feature over 50 invited speakers in 6 main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. Scientific tracks will cover therapeutic areas (e.g. oncology & immunotherapy), innovative technologies (e.g. assay development, screening, chemistry), and target progression challenges (e.g. target identification/validation, translational models). d. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://elrig.org/drug-discovery-2016-programme/ |
| Description | EPSRC Centre for Mathematical Sciences in Healthcare -- Centre Launch Day May 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Launch of EPSRC at UOL bringing together CIs, advisors, industrial and clinical partners, plus other UK Centre reps over for a networking day |
| Year(s) Of Engagement Activity | 2016 |
| Description | EPSRC Liverpool Centre for Mathematics in Healthcare (LCMH) advisory meeting 24.1.2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Advisory meeting exploring and discssuing a rnage of topic son the role mathe,matics play in healthcare main discussion topics 1) Modelling of Spread and Evolution of Infectious Diseases and Complex Networks. 2) Toxin-mediated Competition in Bacterial Communities , 3) Modelling the Evolution of AMR in Shigella 4) Imaging and Data Integration. 3D Segmentation - Methods and Medical Applications 5) Multi-scale Systems in Healthcare Problems. 5) Modelling of Abdominal Aortic Aneurysms Wave reflection in Stented Arteries, 6) Multiscale Modelling of Drug Transport & Metabolism in Mollecular Systems |
| Year(s) Of Engagement Activity | 2018 |
| Description | Edinburgh International Conference of Medicine: Past, Present & Future - 12 & 13 September 2016 RCPE |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This event combine historical aspects of medicine with a glimpse into the future for healthcare across a broad range of clinical topics The audience consisted of a spectrum of healthcare specialists ranging from doctors in training through to senior consultants, nursing, physiotherapist and pharmacists. Lay representatives, historians and patients attended also two speeches given Pharmacogenetic variation - is it important for clinical care?" and what's on the horizon session: Precision Medicine" to link the issues of the background/ historical background to pharmaogenomics and discussing future potential going forward. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.pastpresentfuture2016.org/home |
| Description | FOCUS 2015, the National Meeting of the Association for Clinical Biochemistry and Laboratory Medicine,9-11th June 2015 in Cardiff |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | To assist thinking and understanding to medical and clinical scientist consultants in clinical biochemistry and trainees at various stages to . purpose of this symposium is to update on scientific principles and to highlight any areas likely to be of particular relevance to the hospital diagnostic laboratory. Improved learning and knowledge from audience |
| Year(s) Of Engagement Activity | 2015 |
| Description | Farr Institute International Conference 2015, St Andrews, 26 - 28 August 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | share thinking on the linkage with record darta and health informatics researchers/ policy makers keen n the subject matter of topic of Linking Phenotype and Genotype |
| Year(s) Of Engagement Activity | 2015 |
| Description | Gave Evidence at the House of Commons Select Committee re COVID 19 Response |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Asked to give evidence to the House of Commons Select committee on Science and Technology as part of the Committee's ongoing scrutiny of the UK response to covid-19. The Committee's evidence session is focussing on vaccines. I was asked to attend as Chair of CHM to focus on AZ Vaccines |
| Year(s) Of Engagement Activity | 2021 |
| Description | Genomic Medicine for Clinicians Conference January 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | presented a talk on Pharmacogenomics & genomic drug development which generated discussion and interest in the subject matter interest in the subject matter generated |
| Year(s) Of Engagement Activity | 2015 |
| Description | Gordon Research conference MAINE June 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | a speaker on the topic "Translational Safety & Patient Tailoring" at the 2016 Drug Safety Gordon Research Conference. As an expert and thought leader in that area your contribution would be invaluable to the success of the conference and to openly discuss the current state and future direction of using pharmacogenomics in drug safety assessment. The 2016 Drug Safety GRC builds upon a successful inaugural meeting in 2014 and aims to discuss current and future approaches in drug safety assessment. The goal of our conference is to bridge the divide that exists between individuals working in predictive, pre-clinical and clinical drug safety research, and to foster the translation of innovations from the lab to the clinic. In 2014 session chairs, speakers and participants from academia, industry and regulatory agencies used the opportunity to network and identify current practices and needs in drug safety assessment and to discuss advances, opportunities and limitations of novel translational drug safety methods. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.grc.org/programs.aspx?id=16738 |
| Description | Health is Wealth conference Liverpool Jan 2015 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | The purpose to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation. The purpose of the workshop is to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation. |
| Year(s) Of Engagement Activity | 2015 |
| Description | IBIMA - Malaga march 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Regular seminars are a major part of the Instituto de Investigación Biomédica de Málaga, IBIMA (Malaga Biomedical Research Institute) educational program. The aim of these seminars is to discuss research topics of interest for IBIMA with recognized experts in the field focusing on the most recent scientific discoveries. I Participated in a seminars as a speaker on the topic "Precision Medicine: its application in clinical investigation and practice innovation". |
| Year(s) Of Engagement Activity | 2016 |
| Description | ICAN Series Conference Paris December 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pharmacogenetics in complex human traits title of presentation - sparked discussion and generated new requests for attendance at conferences further requests for information requested |
| Year(s) Of Engagement Activity | 2015 |
| Description | IFCE CONFERENCE PARIS jUNE 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | New Developments in Pharmacogenetics" SPEECH to stimulate thinking Stimualted thnking amongst those present |
| Year(s) Of Engagement Activity | 2015 |
| Description | ISOP AGRA 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Introduced As the host city for ISOP 2017 a prestigious honour to hold the THE Annual meeting on Pharmacovigilance internationally Took part in BREXIT Debate at the ISOP 2016 |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.isop2016agra.org/ |
| Description | ISSX Glasgow June 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | presentation on Implementation of Pharmacogenomics in Clinical Practice-focus on evidence-based medicine and cost-effectiveness". Greater understanding on th need for cost effectiveness for the need of Pharmacogenomics in Clinical Practice |
| Year(s) Of Engagement Activity | 2015 |
| Description | Incorporating Pharmacogenetics into Clinical Decision Support Systems workshop November 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | topics ccovered Challenges of incorporating PGx alerts in decision support systems and with the Professional Record Standards Body Pharmacogenomics and Software as a Medical Device Statistical issues in the development of decision support tools. Industry perspective Delivering actionable pharmacogenomic guidance at the point of care. Enabling precision prescribing with embedded PGx at ANY point of care Routinely use of bioinformatic tools for therapies optimization. Clinical Decision Support for Genomics at Scale: Application to Precision Medicine Multidisciplinary precision medicine programs: a population-based approach. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Integrating Genetics into Clinical Practice event, Oxford 17th April 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Integrating Genetics into Clinical Practice event, Oxford speech tailored to frontline professionals The 1/2 day event, which will be tailored toward primary care physicians, coverered topics such as the genomics landscape in the UK, the evolution of genetic testing, core competencies in genetics, collaborating with genetic counselors in primary care, as well as the use of pharmacogenomics in primary care. |
| Year(s) Of Engagement Activity | 2015 |
| Description | International symposium on Advances in Predictive & Personalized Medicine Istanbul April 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Keynote Speaker Invitation for International symposium on Advances in Predictive & Personalized Medicine Kay note speech focuseed on How to Select Pharmacokinetic Tests for Population Health? Lessons Learned at the UK National Health Service (NHS)". which helped stimulate debate and discussion on the issues around predictive and personlized health |
| Year(s) Of Engagement Activity | 2015 |
| Description | Interview for Times radio RCP REPORT Pharmacogenomics March 29th 2022 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview for Times radio RCP REPORT Pharmacogenomics March 29th 2022 to highlight personalised testing for prescriptions featured in other media outlets also and press releases https://www.theguardian.com/science/2022/mar/29/experts-push-for-genetic-testing-to-personalise-drug-prescriptions https://www.bbc.co.uk/news/health-60903839 https://www.dailymail.co.uk/health/article-10659843/UK-offer-150-genomic-testing-NHS-patients-personalised-prescriptions.html https://www.telegraph.co.uk/news/2022/03/29/common-drugs-do-not-work-properly-70pc-cases/ https://www.dailymail.co.uk/health/article-10659843/UK-offer-150-genomic-testing-NHS-patients-personalised-prescriptions.html https://www.mirror.co.uk/lifestyle/health/nhs-patients-could-offered-100-26578463 Around 300 syndicated reports via the Press Association including: https://uk.sports.yahoo.com/news/nhs-must-introduce-genetic-testing-230100227.html https://www.heraldscotland.com/news/20027373.nhs-must-introduce-genetic-testing-stop-medicines-harming-patients/ https://www.thenational.scot/news/20027373.nhs-must-introduce-genetic-testing-stop-medicines-harming-patients/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.bbc.co.uk/news/health-60903839 |
| Description | Interview with Daily Mail Health editor 29th March 2022 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | to highlight report BPS/ RCP For genetic testing to personalise drug prescriptions https://www.theguardian.com/science/2022/mar/29/experts-push-for-genetic-testing-to-personalise-drug-prescriptions https://www.bbc.co.uk/news/health-60903839 https://www.dailymail.co.uk/health/article-10659843/UK-offer-150-genomic-testing-NHS-patients-personalised-prescriptions.html https://www.telegraph.co.uk/news/2022/03/29/common-drugs-do-not-work-properly-70pc-cases/ https://www.dailymail.co.uk/health/article-10659843/UK-offer-150-genomic-testing-NHS-patients-personalised-prescriptions.html https://www.mirror.co.uk/lifestyle/health/nhs-patients-could-offered-100-26578463 Around 300 syndicated reports via the Press Association including: https://uk.sports.yahoo.com/news/nhs-must-introduce-genetic-testing-230100227.html https://www.heraldscotland.com/news/20027373.nhs-must-introduce-genetic-testing-stop-medicines-harming-patients/ https://www.thenational.scot/news/20027373.nhs-must-introduce-genetic-testing-stop-medicines-harming-patients/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.dailymail.co.uk/health/article-10659843/UK-offer-150-genomic-testing-NHS-patients-person... |
| Description | Joint ASCEPT-BPS Scientific Meeting May 2015 hong kong |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | paper presentation |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | symposium Phenotyping vs genotyping in HK slot of presentation presentation delivered " Has genotyping fulfilled its hopes to individualise drug therapy" and chared a session on Drug Discovery, Development And Evaluation debate stimluated on the presentation delivered " Has genotyping fulfilled its hopes to individualise drug therapy" outlined next steps in this areas |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://ascept-bps2015.com/programme-and-keynote-speakers-2/ |
| Description | Joint CRN/UK Px & Stratified medicine Network Workshop November 2nd 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A Roadmap for Delivery of Stratified Medicine Research in the NHS - the objective of the event is to come up with practical solutions to facilitate the delivery of stratified medicine studies within the NHS with the support of the NIHR CRN. Key areas covered Professor Pirmohamed will provide an overview of the types of challenges associated with the delivery of stratified medicine studies, referring to those identified in the NIHR CRN scoping document (provided in delegate packs) as outlined below; 1 Screening recruits for studies - ensuring resources are available to screen patients and that this activity is recognised. 2 Cross boundary working where research activity for individual patients occurs at multiple sites, including the need to establish new clinical referral pathways where appropriate 3 Activity recognition (including where activity spans more than one site) 4 Streamlining research management and governance 5 Access to diagnostic tests and investigations 6 Opportunities and impact of participation in stratified medicine studies for patients 7 Access to resources to support research activity at all sites 8 Data management and training (such as eRDC) to support delivery of stratified medicine studies 9 Systems and tools for capturing data for stratified medicine studies 10 Links with other infrastructure (such as ECMCs and CRFs) and feeding into pipeline |
| Year(s) Of Engagement Activity | 2016 |
| Description | Joint workshop MHRA - STRATIFIED MEDICINE WORKSHOP June 9th 2016 Regulation of genomic testing |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | To discuss the Regulation of genomic testing and the challenges that arise from patient / professional perspective |
| Year(s) Of Engagement Activity | 2016 |
| Description | Kuala Lumpar - Next generation pharmacogenomics March 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | debate generated personalised medicine the challenging of developing the evidence base students, academics and health professionals debated about such issues to inform discussion |
| Year(s) Of Engagement Activity | 2015 |
| Description | Kuala Lumpar - Visiting Lecturer July 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | Series of talks to University of Malayisia Students and other Universities at undergrad, post graduate and academic staff on a rnage of topics aimed at promoting the realms and possibilities of Pharmacogenetics Promoting the numbe rof opportunities and ideas within Pharamcogenomics |
| Year(s) Of Engagement Activity | 2015 |
| Description | LHP / NICE CONFERENCE liverpool 14.10.2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | dsicussion centred on How genetics can impact healthcare - Increased availability of genetic testing and the future of primary care - The importance of a free NHS in the era of genetic medicine - Opportunities for personalised medicine Increased knowledge and appetitle for Personalised medicine |
| Year(s) Of Engagement Activity | 2015 |
| Description | Launch of Liverpool Alcohol Institute Liverpool January 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Launch of Liverpool Alchohol Institute to promote its role in liverpool wide area It is designed to understand the drivers and consequences of alcohol misuse, and to develop new treatments, interventions and policies in response to Alcohol is the third leading cause worldwide for chronic disease with more than 60 diseases associated with alcohol consumption, including various common cancers. In 2010, 270,624 years of life were lost (deaths under 75 years) due to alcohol in the UK, and the Liverpool City Region has some of the highest rates of morbidity and mortality associated with alcohol in the country. The Liverpool Centre for Alcohol Research (LCAR) will bring together experts from the University of Liverpool, Liverpool John Moores University and local NHS trusts through Liverpool Health Partners to work on the advancement of alcohol-related research and education. It will focus on four main areas of research and practice and, crucially, the multidisciplinary synergies between them: liver (and other end organ) diseases; mental health; cancer; and public health and associated policy. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://news.liverpool.ac.uk/2019/01/21/tv-presenter-helps-launch-new-research-centre-to-tackle-alco... |
| Description | Launch of the NW Coast Genomic Medicine Centre July 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Health professionals |
| Results and Impact | To generate interest in and support for the Launch of the NW Coast Genomic Medicine Centre to promote the issues of NHS Transformation through use of Genomics and precision medicine |
| Year(s) Of Engagement Activity | 2015 |
| Description | MADRID IFCC TF-PG : Task Force meeting 18th March 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | review of work achieved and planned collaboration going forward. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ifcc.org/ifcc-congresses-and-conferences/ifcc-gc-2016-madrid-es/ |
| Description | MHRA Innovation Symposium 30th November London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The MHRA Innovative Medicines Symposium offers industry professionals and academics the opportunity to hear from MHRA and experts from the Commission on Human Medicines (CHM) about regulatory considerations and support for innovative medicines and emerging technologies Regulatory perspectives of emerging technologies presentation delivered - generated and stimulated thining in the cintrolled field of regualtions. |
| Year(s) Of Engagement Activity | 2015 |
| Description | MRC Biannual Directors' Meeting. 18th November 2015 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Information giving wIth colleagues associated with MRC Continued discussion and dialogue on areas of research that affect/ impact and progress research initiatives |
| Year(s) Of Engagement Activity | 2015 |
| Description | MRC BIANNUAL Directors Meeting MAY 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | MRC BI ANNUAL Meeting to discuss areas of interest and progress in MRC activities |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC Biannual Directors November 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | MRC Biannual Leaders' Meetings Programme agenda covered Medical Research Foundation - Professor Nicholas Lemoine, Chair of Trustees Health Data Research UK vision and update - Professor Andrew Morris, Director of Health Data Research UK 1 UK Research & Innovation - Professor Sir Mark Walport, Chief Executive Designate, UK Research & Innovation 1 UKRI Q&A Gene editing in early human embryos, future directions - Kathy Niakan, Programme Leader - developmental biologist at the Francis Crick Institute 15.15 - 16.30 Strategy Update - Declan Mulkeen, Chief of Strategy Science Update - Rob Buckle, Chief Science Officer 16.30 - 16.45 |
| Year(s) Of Engagement Activity | 2017 |
| Description | MRC CDSS Drug Repositioning Workshop (Sudeep Pushpakom) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a workshop organised at the University of Liverpool under the Centre for Drug Safety Science attended by scientists, academia, pharma industry and regulatory agency representatives where the current status of drug repositioning was discussed. |
| Year(s) Of Engagement Activity | 2015 |
| Description | MRC SHOWCASE March 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | showcase the work of the fellows with MRC TO OFFER SUPPORT AND GUIDANCE TO THE FELLOWS Fellows supported and work undertaken recognised and acknowledged |
| Year(s) Of Engagement Activity | 2015 |
| Description | MRC STRATEGIC OUTLINE MEETING 6.2.2017 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Member of MRC EXPERT PANEL |
| Year(s) Of Engagement Activity | 2017 |
| Description | MRC Toxicology Unit - Masterclass invitation November 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | invited to give a masterclass on a topic of choice followed questions and answers. the talk is followed with a discussion with the host and lab members PHD Students, post docs and then brief 1:1 meetings with other Programme Leaders. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Manchester Science Spectacular 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Manchester Science Spectacular runs annually and is an opportunity for scientists to showcase their research work to an audience of children and families. The event is attended by approximately 1,500 people. Interactive table top activity aimed at families and children to teach about medicine and where it comes from as well as personalised health. Several MRC Fellows took part in the event. Approximately 100 children took part in this activity. This is the fourth year MRC Fellows have taken part in this event and the stand Marvellous Medicine has become a regular acticity stand at this event. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Manchester Science Spectacular 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Clinical Research Fellows on the North West England MRC Fellowship Scheme joined with several PhD students from the MRC Centre for Drug Safety Science to take part in the 2017 University of Manchester Science Spectacular, an annual event that forms part of the Manchester Science Festival. The Research Fellows and the PhD students ran an activity stand called 'Marvellous Medicine' which explained a little bit about where drugs come from and how clinicians make decisions about how to use them. However the main focus of this year's activity was to explain the use of immunotherapy in treating cancer using a skittles game. The Science Spectacular is normally attended by approx. 1,500 people and we estimate that approximately 100 guests visited the activity stand. The verbal feedback we received on the day from both adults and children was very positive. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/ |
| Description | Medicine in 1925 and in 2015: a symposium to mark the 90th Anniversary of the Postgraduate Medical Journal 1st october 2015 London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | presentation Progress in Personalised Medicines stimulated debate in the advancements of medicine from 1925 to present day. request for further information in respect of topics covered in speech |
| Year(s) Of Engagement Activity | 2015 |
| Description | Meeting with Justin Madders Shadow Health Minister / Lord Hunt re Clinical Pharmacology in NHS |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Promotion of Clinical Pharmacology in NHS |
| Year(s) Of Engagement Activity | 2016 |
| Description | Meeting with Rt Hon Sir David Willets MP 2ND June 2016 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Discussion with Rh Hon David Willets on work undertaken at the Wolfson centre for Personalised medicine and future initiatives and research areas. engagement with staff , research nurses , Post docs was undertaken to demonstrate the broad scope of work undertaken. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Meeting with The Rt Hon Lord Hunt of Kings Heath PC OBE, Deputy Leader of the Opposition 4.5.2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | discussion with The Rt Hon Lord Hunt of Kings Heath PC OBE, Deputy Leader of the Opposition in relation to Highlighting CPT / Clinical Pharmacology in NHS outcome PQs will be raised on topic |
| Year(s) Of Engagement Activity | 2016 |
| Description | N8/MRC Visit to University of Liverpool 25 04 2016 to discuss target in new Medicines |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Some thoughts from MRC colleagues on their strategic priorities followed by round table discussion and agreement on any next steps. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NIHR Global Health meeting 6-7th June 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | 2 day event bringing all recipients of NIHR global health funding awards together to discuss What NIHR brings to the global health funding landscape the support NIHR can offer recipients in terms of training and development, Governance support and providing the forum for networking opportunities with other recipients Publication and open access Elaine Williams, Director of Research, NETSCC Managing Intellectual Property Lee Allen, Senior Programme Manager, NIHR Intellectual Property Unit Transparency Alec Jackson, Programme Officer, Department of Health and Social Care Panel Q&A Coffee/tea and refreshments Surgery tables: • Monitoring of ODA spend and reporting on project progress via the Management Information System Stephanie Russell, Lisa Marsh, Nicola Porteous • Project Outputs and Open Access Requirements Elaine Williams, Sarah Moss, Naomi Williams, Rachel Henderson • General questions related to GHR and ODA funding Sarah Puddicombe, Val Snewin • Managing Intellectual Property Lee Allen, Lucy Knight, Intellectual Property Manager • Transparency Alec Jackson Identifying and addressing challenges Break out discussions to discuss specific issues raised in advance, followed by facilitated session to share issues/ themes and potential solutions. |
| Year(s) Of Engagement Activity | 2018 |
| Description | NWAC - ALCHOHOL CONFERENCE Liverpool 20th November 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Free conference to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines. Discussions is again free to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines. Discussions on the international, national and local perspectives will be supplemented by the showcasing of good practice examples and shared learning from practitioners across the country. NWAC15 provided an unparalleled learning opportunity to exchange thoughts with peers, and build awareness of the range of approaches taken to reduce the harm caused to individuals and communities by alcohol abuse. Participant advised that they left with insight which improved their own practice for patients and service users, as well as greater knowledge on how the national agenda is shaping up. |
| Year(s) Of Engagement Activity | 2015 |
| Description | National Training Day for SpRs in Clinical Pharmacology |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | to assist with training as part of National Training Day for SpRs in Clinical Pharmacology More infiormed trainees. |
| Year(s) Of Engagement Activity | 2015 |
| Description | PGX and Strat Med Network meeting - Cambridge Jan 15 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This meeting brought together leaders from academia, regulatory bodies, healthcare organisations, pharmaceutical and diagnostics industries to discuss recent progress in this area. focus was on the UK environment for stratified medicine and will review current public and regulatory perceptions. It will also highlight developments in clinical trial design and advances in key areas of research; including pharmacogenomics, rare diseases, rheumatoid arthritis and cancer. Sharing of information and recnet changes in areas of stratified medicine |
| Year(s) Of Engagement Activity | 2015 |
| Description | PHARMACOLOGY 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Key role in supporting the work of BPS to promote and advance pharmacology, including clinical pharmacology in the following ways: Assist, promote and encourage research and provide a forum for the presentation of pharmacology Publish the results of research Promote and encourage the education and training of pharmacologists Publish resources in various forms Promote and arrange conferences and meetings Promotion of CPT in NHS is key objective |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015 |
| Description | PHARMACOLOGY 2015 LONDON |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | workshop facilitator |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Generated discussion regarding CPT in NHS and the whole area of Pharmacology within UK |
| Year(s) Of Engagement Activity | 2015 |
| Description | PHARMARELA8 CONFERENCE February 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | debate on Genomics and therapeutics generated discussion on future direction of genomics and into impact in therapeutics |
| Year(s) Of Engagement Activity | 2016 |
| Description | PHRMY Research Seminar: Cardiff University March 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Talk - Improving drug safety - a multifunctional approach asked to deliver a talk at Cardiff seminar due to long-standing interest and expertise in Pharmacovigilance and Drug Safety |
| Year(s) Of Engagement Activity | 2021 |
| Description | PODCAST with Genomics England re launch of Personalised Prescribing report |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The aim is to improve understanding around genomics both within and beyond the healthcare and academic community. |
| Year(s) Of Engagement Activity | 2022 |
| Description | PODCAST with Professor Albert Farro for Medicine Journal 50th Anniversary interviews |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | asked by Prof Albert Farro in his capacity as chairman of the editorial board of the journal Medicine. ,( evidence-based learning resource for trainees )- It is a great tool to help trainees achieve their postgraduate medical qualification, wherever they are in the world. It provides a concise overview of the latest medical knowledge and practice based upon the UK Internal Medical Training curriculum, with each article written by invited qualified experts. The journal is celebrating its 50th anniversary this year, and as part of the events to mark this a series of podcasts on a variety of topical issues. , the proposed subject being the role of pharmacogenomics in healthcare - present and future? |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.medicinejournal.co.uk/ |
| Description | POLANI LECTURE February 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | POLANI LECTURE at Guys hospital makeup of the audience was geneticists, bioinformaticians, immunologists, dermatologists, clinicians, research workers (ranging from heads of groups to research students), and other interested parties. confirmed title Precision Medicine and Drug Safety: Opportunities and Challenges" followed by informal chat with Students |
| Year(s) Of Engagement Activity | 2016 |
| Description | PPI Engagement event 8th April 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | PPI patient group updated on progress within the international community of progress made in thinking on SJS/ TEN the PPI team where invigorated by the progress made internationally to raising awareness of SJS/ TEN and impacts it has going forwatd to raise greater understanding and awarness of healthcare professionals. |
| Year(s) Of Engagement Activity | 2015 |
| Description | PSMN WORKSHOP LONDON NOVEMBER 11TH 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Work shop identified and highlighted progress and innovation in the filed of stratified medicine. Ability to learn from industry and other collaborative partners on future direction of stratified medicine |
| Year(s) Of Engagement Activity | 2015 |
| Description | Parliamentary Reception 14th december 2015 - BPS |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | To discuss and promote CPT guidance in NHS further request for attendance at NHS England meetings and with chief medial officers in Scotland, Ireland and Wales |
| Year(s) Of Engagement Activity | 2015 |
| Description | Parliamentary reception 12th December 2016 Pharmacology's role in bridging the skills gap in UK bioscience industry" and to be joint with the ABPI. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | attended event as a representative of BPS On behalf of Stephen Metcalfe MP, to attend a special Parliamentary Reception, 'Is UK pharmacology a world leader? Bridging the skills gap in the biopharmaceutical industry'. The reception will be hosted by the British Pharmacological Society in collaboration with the Association of the British Pharmaceutical Industry (ABPI). |
| Year(s) Of Engagement Activity | 2016 |
| Description | Personalised Medicine Conference in Oxford April 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The conference is jointly organised by the Centre for Personalised Medicine in Oxford (a collaboration between the Wellcome Trust Centre for Human Genetics in Oxford and St Anne's College) and the PMWC A series of these conferences, organised by PMWC, have been held very successfully every year in Stanford. The Oxford conference will be the first of this series in Europe. 300 people, drawn from industry, academia, and the healthcare sector, to gather in Oxford across the three days for a conference focused on where personalised medicine fits in the clinic and on the practical applications of personalised medicine both now and in the near future. insights and expertise in my role as NHS Chair of Pharmacogenetics provided a valuable addition to the conference |
| Year(s) Of Engagement Activity | 2015 |
| Description | Personalised healthcare sensor event 15th March 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Event raised and explored the issue of Mobile Health and Sensor Technologies as key drivers for Better self-management of illness, Point of care monitoring, and moving clinical care from secondary to primary care and outlining the key challlenges of Patient acceptability of biosensors Integration and big data Application and interoperability Changing clinical pathways Technological needs - near patient testing |
| Year(s) Of Engagement Activity | 2016 |
| Description | Personalized Medicine 2015 Conference - Saudi Arabia 5th May -7th May |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Arab world has been under represented in International genome studies. The structure of the Arab population has much to offer in the field of genomics and are attempting to address this through the Saudi Human Genome Program. the talk assisted in enabling the hospital to continue this work However, the greatest challenge faced is in leveraging their genome program to address cancer, cardiovascular disease, obesity, diabetes and other common disorders and to deliver the promises of personalized medicine. Pharmacogenetics is central in all of these areas It has also opened up opportunities to collaborate in a way where the unique population in which we work may be used to supplement international efforts in progressing pharmacogenetic investigations. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Pharmacogenomics in the NHS Joint working party of the BPS and the RCP |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Joint working group Established following the publication of BPS + RCP Joint Report - Next steps preparing to mainstream Pharmacogenomics in clinical practice - BPS + RCP Joint Report - building on the recommendations outlined n the report. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Pharmacogenomics in the NHS working party |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pharmacogenomics in the NHS working party group established between BPS and RCP to ensure Pharmacology is highlighted on national stage a series of meeting held to produce a report to showcase Pharmacogenomics |
| Year(s) Of Engagement Activity | 2021 |
| Description | Pharmacogenomics: A tool for precision medicine meeting organised by the Medical Genetics Section of the Royal Society of Medicine. NOVEMBER 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pharmacogenomics: an overview for the uninitiated f you are interested in finding out about how precision medicine is set to revolutionise medical practice, do not miss this event! The section meeting focused on Introduce healthcare professionals to the concept of pharmacogenomics Provide a realistic overview of the likely impact of pharmacogenomics in modern medicine Share speciality-based experience of the role of pharmacogenomics in stratifying treatments to individual patients with an Explanation of how stratification in precision medicine can be achieved |
| Year(s) Of Engagement Activity | 2016 |
| Description | Pharmacology 2016 London 13th -15th Decemeber |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Pharmacology is the flagship annual meeting of the British Pharmacological Society and attracts over 1,000 scientists each year, mostly from the UK but also many from across Europe and from overseas. The meeting includes a selection of topical symposia, plenary lectures, free oral communications and poster sessions which cover the whole spectrum of pharmacology. key topics covered Cardiovascular and Respiratory Pharmacology From bench to bedside: targeting the pathophysiological responses of ischemia-reperfusion injuries Targeting cardiovascular GPCRs using biased agonism Nanomedicine in pharmacology Neuropharmacology Uses and challenges for human pharmacology studies to understand CNS diseases Fatty acid amides (aka lipoamines) beyond cannabinoids Recent developments in research of melatonin and its potential therapeutics application Integrative Systems Pharmacology The long reach of the bowel: Translating microbiome science into therapeutics for systemic human diseases Study, development and rationale use of immunopharmacological agents Immuno-oncology: From bench to bedside Translation to Therapeutics: Resolution of Inflammation Molecular and Cellular Pharmacology Non-traditional/orphan GPCRS as novel therapeutic targets Biochemical strategies in drug discovery and targeting Anti-tumor pharmacology and traditional Chinese medicine Drug Discovery, Development and Evaluation and Toxicology Organ-on-a-chip technology - the future of physiological profiling? Clinical application of systems pharmacology models Clinical pharmacology, pharmacokinetics and pharmacogenetics in pregnancy (C4P) |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.bps.ac.uk/pharmacology2016#Programme |
| Description | Plenary talk at British Oncology Pharmacists Symposium Manchester -October 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | 19th Annual BOPA Symposium being held at Manchester Central. The BOPA Annual Symposium is a highly significant event in the UK oncology and pharmacy calendars, attracting over 500 delegates, 40 pharmaceutical companies, and representatives of cancer charities, the NHS and government bodies involved in the delivery and co-ordination of cancer services. Delegates are pharmacists and pharmacy technicians involved in the care of cancer patients and the management of pharmacy and chemotherapy services in cancer centres, primary care and NHS England organisations. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.bopawebsite.org/user/login?maintenance=mode |
| Description | Pod cast |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Undergraduate students |
| Results and Impact | Approached by Laureate to produce a number of podcasts with UOL to help promote the University's research TOPIC University's approach to personalised health. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Public Engagement Workshop 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | This public engagement event ran on 16th June 2015. There were approximately 50 attendees. The aim of the workshop was to help researchers and students understand pubic engagement. We had a variety of speakers, from Press Officer professionals to a Wikipedia expert. The event was well received with a lot of positive feedback. |
| Year(s) Of Engagement Activity | 2015 |
| Description | RCP advanced medicine conference Feb 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | talked on the topic of 'Important drug interactions' and chaired the session on pharmacology The event is a long-running and integral part of the annual RCP conferences programme t is designed to provide advanced medicine training to all physicians and to cover latest cutting-edge advances in clinical practice, underpinned by an improved understanding of the disease mechanism. The conference is one of the RCP's most high-level academic programmes and it's important to present the most cutting-edge scientific advances from across the specialties. |
| Year(s) Of Engagement Activity | 2016 |
| Description | RCPE Midlands Symposium, April 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | The RCPE organises a number of regional symposia in different parts of the UK. All grades of medical and other healthcare staff attend Topics covered on the day included cardiovascular medicine, gastroenterology, complex care of older people and stroke medicine, with the Dr Andrew Duncan Lecture delivered by Professor Sir Munir Pirmohamed on the topic of Personalised Medicine - How will it shape medicine in the future |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://events.rcpe.ac.uk/events/409/regional-symposium-midlands |
| Description | SAPhIRE SRC meeting and Symposium Singapore May 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | to focus on activities in Singapore / far east on issues surrounding pharmacogenomics in South east Asia and its development |
| Year(s) Of Engagement Activity | 2016 |
| Description | SJS AWARENESS LAUNCH February 2015 - London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | To raise awareness of Stevensd Johnson syndrome at an event in Hosue of Commons to gain support form Decision makers to raise awareness of SJS and to request support for a national awareness day for SJS , Committment to raise awareness of SJS amongst health professionals |
| Year(s) Of Engagement Activity | 2015 |
| Description | SJS/TEN CONFERENCE BETHSEDA MARCH 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | iSAEC and what has been done in this area stimulated discussion in this area and what advancements can be made sharing of information and a greater understanding of work being undertaken in other countries such as Malaysia and Thailand |
| Year(s) Of Engagement Activity | 2015 |
| Description | Sanger Institute BioData World Congress October 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | its second year is held in partnership with: The Wellcome Trust Sanger Institute, EMBL-EBI, Global Alliance for Genomics and Health, Babraham Institute, ABPI, Pharmacogenetics and Stratified Medicine Network, BIA, Pistoia Alliance, Cancer Research UK, Francis Crick Institute and the Farr Institute. I very much would like you to give a presentation at the meeting as I am well aware of the work that you are you are conducting in field. This year's event will: • Examine the science and technology that is shaping and revolutionising our understanding of complex biological processes • Review the game changing innovation, roadblocks, critical success factors in the utilisation of bio data • How big data is driving developments in personalised medicine • Bring senior scientists within academia, pharma and biotech companies in order to facilitate discussion and partnerships The meeting covered • Personalised Medicine • Clinical trials • Computational biology • Big Data • Cloud computing • High throughput technologies • Next generation sequencing • Pharmacogenomics • Molecular diagnostics • Biomarkers • Infrastructure and security • Data handling and management Presentation on "Advances in the Pharmacogenomics of Adverse Drug Reactions" |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.healthnetworkcommunications.com/conference/biodatA/index.stm |
| Description | Scientific Advisory Board Meeting NOVEMBER 2016 LONDON |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | AIM HY Original MRC Grant Application scientific meeting to determine requirements and support for grant |
| Year(s) Of Engagement Activity | 2016 |
| Description | Scientific briefing on AZ DRUG Effects - COVID |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Scientific Briefing via Media broadcasters to the public regarding the safety concerns of AZ drug - To reassure the general public of its safety |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement |
| Description | Singapore - joint scientific advisory board STAR BOARD |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | the BMRC decided that they will use the title 'Scientific Review Committee' for any expert committee advising upon a research programme. improved understanding and increased collaboration sam |
| Year(s) Of Engagement Activity | 2015 |
| Description | Statin-induced muscle toxicity: evaluating the functional effects of variability in P450 oxidoreductase (2015) (Richard Myles Turner) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | I gave an oral presentation at the University of Liverpool Institute of Translational Medicine Research Day covering my PhD fellowship project rationale and results to date (2015). This led to interesting and productive conversations. This activity provided publicity for both my project and the MRC fellowship scheme that I am currently enrolled on. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Stratified Network Open meeting 15.6.2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Annual Open meeting Theme Working together to deliver personalised/precision medicine focussing on advancements in precision medicine and the application of these into medicine |
| Year(s) Of Engagement Activity | 2022 |
| Description | Summer School GENOMIC MEDICINE - Bridging research and the clinic Portorož, Slovenia May 2016. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | shared expertise with the participants of the summer school and participate in the scientific programme. The program covered a wide range of topics related to genomic medicine ), pharmacogenomics and epigenomics and translation of basic research into clinical practice and public health. Important topics of interest were identification of predictive and prognostic biomarkers and novel molecular targets for tailored therapeutic interventions for diseases linked to oxidative stress and age-related diseases and disabilities. Rare diseases and rare cancers, especially epidemiology, pathogenesis/pathology, and treatment modalities for pancreas cancer will be among the topics of the school. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://ibk.mf.uni-lj.si/genmed2016 |
| Description | Surgical 1921 Committee of England and Wales lecture November 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | the surgical specialties in attendance appreciate talks about research of significance or general application to clinical practice. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Talk at Faculty of Pharmaceutical medicine 17th May 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Precision medicine is a move away from a 'one size fits all' approach to the treatment and care of patients with a particular condition, to one which uses new approaches to better manage patients' health and targets therapies to achieve the best outcomes in the management of a patient's disease or predisposition to disease. Precision medicine is the exciting and evolving new branch of medicine that is seeing medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. New possibilities are emerging, as novel approaches, such as whole genome sequencing, data and informatics, and wearable technology are becoming increasingly utilised. In this exciting conversation event, we are honoured to be joined by three of the leaders in the field to hear their views on the current state of the science and practice of precision medicine and their projections for the future. The audience will be given the opportunity to join the discussion, give their own ideas and learn from these varied perspectives. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Talk at Salford NHS Trust departmental academic neurosciences meeting March 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | An approach was made to speak on the topic of Precision medicine approaches in neurology following a speech given at a pharmagenomics conference. the presentation was tailored specifically for neurology consultants and teams to provide an overview of the benefits of precision medicine. |
| Year(s) Of Engagement Activity | 2018 |
| Description | The 21st International Reid Bioanalytical Forum (2015) Dried blood spot assay development poster presentation (Richard Myles Turner) (Richard Turner) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Richard Turner was involved in the assay development and data acquisition that was presented at this international conference by Dr Mark Bayliss within a poster entitled, 'Dried-blood spotting combined with fused core HPLC-MS/MS for the measurement of atorvastatin, simvastatin and rosuvastatin in support of PK studies in the mouse'. Authors listed are: Bayliss M, Turner R, Kitteringham N, French N, Park K, Pirmohamed M. The presentation sparked further talk regarding micro-sampling techniques, and we were informed about a potential new card material that should overcome the haematocrit limitation of current dried blood spot technologies. This activity provided publicity for our ongoing work |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.bmss.org.uk/Docs/BioForum%202015%20second%20circular%20FInal2-1.pdf |
| Description | Times Educationa Supplement |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Undergraduate students |
| Results and Impact | Contributed to Article in the Times Educational supplement on a case study "Where every patient receives the right drug at the optimum dose " |
| Year(s) Of Engagement Activity | 2018 |
| Description | UK PGx Network Open Targets Workshop October 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | UK PGx Network Open Targets Workshop Panel discussion Approaches for Identifying and Prioritising Targets in Drug Discovery: Exploring the opportunities for where Pharmacogenetics and Disease Stratification can contribute to making safer and more effective drugs • Open Targets: overview and how we enable target prioritisation • UK SPINE: overview and drug discovery pipeline • Druggable Genome joint research project for prioritising targets related to ageing/ |
| Year(s) Of Engagement Activity | 2022 |
| Description | UK PGx Network Virtual Workshop - Polygenic Risk Scores: Current Status and Future Utility - |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | workshop on Polygenic Risk Scores focussing on key areas Genomic profiling for prediction of Alzheimer's disease risk Training and validation of polygenic risk scores in diverse ancestries Impact of PRS on insurance RGA Clinical utility and polygenic scores Genome-wide polygenic risk scores and PCSK9 inhibition with Alirocumab key areas of workshop to discuss 1 - How can we further develop the utility of PRS? 2 - What will be the challenges and opportunities of implementing PRS into clinical practice? 3 - Ethical issues associated with the use of PRS. |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://www.uk-pgx-stratmed.co.uk/index.php/component/jevents/eventdetail/696/23/ukpgx-network-virtua... |
| Description | UK PGx Spring Workshop April 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | aim of workshop in conjunction with MHS England was to discuss and take forward the Re-engineering of clinical pathways to facilitate implementation of personalised medicine featuring six talks to outline existing strategies and pathways. delegates discussed Barriers to changing clinical pathways for personalised medicine Patient and clinician involvement in pathway change and implementation Use of electronic technologies to aid re-engineering of clinical pathways |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.uk-pgx-stratmed.co.uk/index.php/latest-news/31-news/latest/385-ukpgx-spring-workshop-2016 |
| Description | UK Pharmacogenetics & Stratified Medicine Network Open Meeting March 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The Precision Medicine Catapult, the UK's innovation centre for precision medicine, and UK UK Pharmacogenetics and Stratified Medicine Network. are workig together in a strategic partnership to work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes. 'The UK Pharmacogenetics and Stratified Medicine Network has connected many of the leading stakeholders in the precision medicine landscape, two organisations to partner and deliver engagement . The two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.uk-pgx-stratmed.co.uk/images/stories/pdf/UKPGX2016_Programme.pdf |
| Description | UK Prix Galien Committee meeting and judging panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Judging committee panel member for UK Prix Galien Committee meeting |
| Year(s) Of Engagement Activity | 2022 |
| Description | UKPGx Open Meeting October 2021 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The UK Pharmacogenetics & Stratified Medicine Network i Session One introduced by Professor Sir Munir Pirmohamed and featured talks from Dr June Raine, and Erik Ingelsson from GSK. Session Two showcase the work of early career researchers Session Three addressed s COVID-19. Professor Sarah Gilbert spoke on the topic of vaccine development as part of pandemic preparedness, Professor Sharon Peacock delivered the talk "In pursuit of actionable information derived from SARS-CoV-2 genomes," and Dr Clark Russell discussed the genetic mechanisms of critical illness. Session Four looked to the future, featuring Professor Stuart Ralston and Dr Pearse Keane, closing with Professor Dame Anna Dominiczak's intriguing talk "Precision Medicine - What is the Future?" |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://www.uk-pgx-stratmed.co.uk/ |
| Description | UPGX MEETING GRANADA 1ST DECEMBER 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | talk focused on Genomics of drug hypersensitivity reactions This event is open for healthcare professionals, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics. The U-PGx project aims to address major challenges and obstacles for implementation of pharmacogenomics (PGx) testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach, data on multiple important pharmacogenes are collected prospectively and embedded into the patients' electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalized medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia) |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.goldenhelix.org/index.php/education/golden-helix-conferences/pharmacogenomics-days/upcomi... |
| Description | UPGX MEETING LEIDEN JULY 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Working group to discuss UPGX protocol |
| Year(s) Of Engagement Activity | 2016 |
| Description | Utrecht Institute for Pharmaceutical Sciences (UIPS) of Utrecht University October 2016 - Keynote speech |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | symposium "Bioinspired therapies UIPS is conducting research from molecule to patient populations, where our division of Pharmacoepidemiology & Clinical Pharmacology is focused on the last stage of drug development. |
| Year(s) Of Engagement Activity | 2016 |
| Description | VII Conference of the Spanish Society of Pharmacogenetics and Pharmacogenomics April 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary Lecture in the VII Conference of The Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) Talk on "Human genomic variation for personalization of drug treatments, from single genes to the genome-wide era", 2-days conference focused on recent progress in pharmacogenetics and pharmacogenomics. Some of the subjects discussed will be: - International projects and new technologies in human genetics - New advances in pharmacogenomics, consortia and novel working strategies - Personalization of oncology treatments - Implementation of pharmacogenetics in the clinic This meeting will include 2 plenary lectures by international renowned experts in the field, 20 invited talks from speakers belonging to different Spanish institutions, and about 120 participants, who will have the opportunity to present their work in poster sessions and, at the discretion of the organisers, give short talks. This format is aimed at facilitating extensive discussion of current issues and at stimulating new ideas. Most presentations will be carried out in Spanish, however, slides will be in English to facilitate discussion. Human genomic variation for personalization of drug treatments, from single genes to the genome-wide era", focus of discussion was 2-days conference focused on recent progress in pharmacogenetics and pharmacogenomics |
| Year(s) Of Engagement Activity | 2015 |
| Description | Video story for University of Edinburgh |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | a request was made to undertake a short "video story" about the NEJM trial of genotype targeting of Warfarin therapy. explainIng why i did the trial, what it showed and discussed the clinical implications. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Visit by Japanese National Institute of Health Sciences Ministry of Health, Labour and Welfare |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Visit by National Institute of Health Sciences Ministry of Health, Labour and Welfare to the Wolfson centre for personalized medicine and seminar given Pharmacogenomic studies on adverse drug reactions in Japan Dr. Ryosuke Nakamura , PhD., National Institute of Health Sciences (NIHS), Ministry of Health, Labour and Welfare (MHLW), Tokyo, Japan the visit lasted whole day focussing - on association studies between biomarkers and severe adverse drug reactions (sADRs) for promotion of precision medicine. SJS/TEN, exploratory studies on genetic biomarkers related to sADRs including myopathy and drug-induced liver injury for Japanese patients. Sample collection for retrospective case-control study, and patient recruitment for cohort study of sADRs. , harmonization of diagnostic criteria of sADRs ( especially for myopathy and progress on pharmacogenomic studies. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Visit to collaborator sites in Uganda and Cape Town for NIHR Global award |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Collaborator visit to Uganda and South Africa to meet the teams involved with the Global Health award on Warfarin Patients met, practioners discussed the practicalities associated with the project and new networking opportunities and collaborators associated with the visit |
| Year(s) Of Engagement Activity | 2017 |
| Description | Wellcome Trust Workshop on Pharmacokinetics/Drug Interactions MARCH 2015 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | workshop around the general topic area of pharmacokinetics/drug interactions to explore emerging opportunities and to link researchers with complementary expertise and interests. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Wolfson Centre Patient Involvement Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | We have established a patient and Public Involvement group. The purpose of the group is to offer the opportunity for group members to work alongside researchers during the set up and conduct of research studies. Ongoing. We are working with the patient group to establish an awareness campaign about Stephen Johnson Syndrome aimed at clinicians. We are also supporting the 'SJS Awareness UK' group by updating patient information on their website. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Workshop Safety of Immune Checkpoint inhibitors Feb 2018 Liverpool |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop to discuss Safety of Immune Checkpoint inhibitors as prt of the centre for Drug safety |
| Year(s) Of Engagement Activity | 2018 |
| Description | YC 50th anniversary Edinburgh March 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | DISCUSSED THE ROLE OF Pharmacogenomics and the potential for the Yellow Card Scheme to stimualte thinking discussion of the importance of yellow card scheme to best develop linking it to pharmacogenomics |
| Year(s) Of Engagement Activity | 2015 |
| Description | Yellow Card celebration event Liverpool April 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Health professionals |
| Results and Impact | to celebrate 50 years of the Yellow Card -an event was he;ld in merseyside to celebrate work undetaken as part if yellow card scheme presentation focussed on The Yellow Card Scheme the current research and future developments greater understanding of work of yellow card and impact an d difference it has made . plans discussed for future of yellow card |
| Year(s) Of Engagement Activity | 2015 |
| Description | pharmacogenetics-conference .South Africa April 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Genomics research is on an upward trajectory in Africa since the inception of H3Africa and the event has showcased there are very good papers from across Africa and around the world. lectures Genomics and Therapeutics plenary lecture and speech Genomics of the bug and host as determinants of drug response |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.pharmacogenetics-conference.uct.ac.za/ |